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      The centrosome functions as a microtubule-nucleating organelle for the mitotic spindle. 
Like the whole genome, centrosomes require accurate replication once per cell cycle. Here 
we show that the impairment of centrosome composition by depletion of centrosomal 
components or by the inhibition of centrosomal protein PLK4 reduces the progression of DNA 
replication forks in cancer cells. Importantly, the reduction in fork progression occurs even 
when the cells cycle are arrested at the G1 phase before damaging the centrosomes, 
excluding mitotic failure as the source of replication stress. Mechanistically, the kinase MLK3 
associates with centrosomes. When the centrosome composition is impaired, MLK3 activates 
the kinases p38 as well as MK2/MAPKAPK2. RNA:DNA hybrids (R-loops) leading to DNA 
replication stress occur upon activation of the transcription factor JUN, which is a downstream 
target of p38. Finally, fibroblasts from Seckel syndrome patients harboring defective 
centrosomes showed replication stress, which was alleviated by inhibition of MK2. Similar 
replication stress has been observed upon deletion of the kinase ATR, and this genetic defect 
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2.1 Overview of Centrosomes 
 
      Centrosomes are known to be the microtubule-organizing centers (MTOCs) of animal 
cells. They play their most prominent role during mitosis, in which they form two poles of the 
mitotic spindles. They associate with microtubules that, at their opposite ends, attach to 
chromosomes via kinetochores to separate the sister chromatids from each other (1, 2). 
Eduard Van Beneden discovered centrosomes in 1883, followed by their description in 1888  
by the German biologist Theodor Boveri (3). Decades of studying centrosomes helped us to 
understand these organelles further, from revealing their exact structure to their duplication 
cycle to identify their multiple functions to conceal their contribution to human diseases. 
Nowadays, we know that centrosomes not only play a significant role in driving cell division 
but also are involved in the formation of cilia, cell adhesion, cell polarity, cell motility, and 
intracellular trafficking of proteins and organelles (4, 5).  
 
      Structural studies have revealed that each centrosome consists of two barrel-shaped 
centrioles (the mother and the daughter centriole), which are linked together in an orthogonal 
configuration. Both centrioles are highly alike in composition, yet they differ in the consistency 
of distal and sub-distal appended proteins,  which mostly belong to the mother centriole and 
are mainly responsible for cilia generation and anchoring of microtubules (1). The mother 
centriole is responsible for nucleating and organizing microtubules, whereas the daughter 
centriole can only nucleate microtubules. Both centrioles are surrounded by a cloud of proteins 
called pericentriolar material (PCM) (Fig. 2.1). The PCM consists of several centrosomal 
proteins that have multiple functions such as centrosome duplication, maturation, and 
separation by the end of the cycle. Each centriole contains nine triplet microtubules arranged 
as a cylinder-like structure in a 9+3 pattern known as cartwheel structure (8). As centrosomes 
progress towards mitosis, additional proteins will be recruited to the site of centrosomes, e.g., 
PLK4, PLK1, and CDK2 (98). 
 
      Centrioles require permission to carry with their duplication cycle; such permission can 
be acquired merely after the cells pass the M phase. Two steps govern the process of centriole 
duplication: the disengagement of centrioles by PLK1 and Separase at the G2-M phase, and 
the conversion of centriole-to-centrosome (4, 6, 103). After loosening the centriole 





polo-like kinase (PLK4) by the scaffold protein CEP152 and CEP192 in early G1-phase. Once 
PLK4 is recruited to the site of centrosomes, it will start a cascade of centrosome proteins 
phosphorylation, which will be explained in detail in the next section. As the cell progresses to 
S/G2 phase, these newly formed procentrioles assemble their cartwheel and continue to 
elongate until they reach the length of the old mother-daughter centriole, for the reason that 
each "mother centriole" serves as a template to build up a new daughter centriole (6). Once 
the newly born centrioles are fully matured, the two centrosomes start to migrate apart from 
each other towards the cell poles, allowing chromosome segregation during the next cell cycle 


















Figure 2.1: Centrosomes are multiprotein complexes that are replicated once per cell cycle — 
detailed scheme of the fully matured centrosome. A nine-fold symmetry in microtubule triplets of the 
two centrioles (mother and daughter in green) and essential protein components of the pericentriolar 
material (PCM) that were identified to date are shown. Targets addressed in experiments of this study 








2.2  Centrosome duplication cycle  
 
      In dividing cells, centrosomes form bipolar spindles to organize chromosome 
segregation. Each daughter cell inherits one centrosome from the mother cell and thus needs 
to duplicate this centrosome once per cell cycle. Like DNA replication, centrosome duplication 
is a crucial process within the cell, and therefore it is highly regulated by cell cycle-coupled 
processes that are essential to ensure the only one-time duplication per cell cycle. Once the 
cell is at the G1/S transition, each pre-existing centriole will start forming their pro-centriole, 
which will remain in a close distance to their parent's centrioles till late of G2 (9-12). 
 
Licensing centriole duplication is not an exclusive process for centrosomes based 
proteins; like PLK1 and Separase (103,118), but also cell cycle several regulators are involved 
in monitoring and controlling the faith of the centrosome duplication process; for example, the 
centrosome cycle is mediated by cyclin-dependent kinase 2 (CDK2) (98), cyclin A and cyclin 
E (9). Several studies proposed that CDK2 has many substrates that are responsible for the 
regulation of centrosome duplication. These substrates mainly include Centriolar Coiled-Coil 
















Figure 2.2: Cell cycle vs. the centrosome duplication cycle. Both cycles are being regulated and 






      Initially, the centrosomal proteins CEP152 and CEP192 recruit polo-like kinase 4 
(PLK4) and locate it on the mother centriole, where the new centriole will be built (10, 11).  
The recruited PLK4 will then bind to centrosomal protein STIL, and upon this binding, PLK4 
will experience conformational changes, which will lead to its activation (10,11). Activation of 
PLK4 then will then phosphorylate STIL, triggering the recruitment of spindle assembly 
abnormal protein 6 (SAS6) to form the "core module for centriole duplication" (12).  
 
      While STIL is targeted by phosphorylation of PLK4 (12,13), SAS-6 self-assembles into 
a cartwheel, forming the basis of the central tube for nucleation of microtubule triplets in a 
nine-fold symmetry (14, 15). Despite the lack of knowledge in the downstream events of 
centriole duplication, yet there are some clues that CEP135 helps to connect SAS-6 to the 
outer microtubules of the microtubule triplets (15,16).  As cells progress through S-phase and 
towards G2-phase, daughter centrioles on both mother centrioles need to be elongated. The 
length of newly born centrioles is controlled by the centrosomal proteins CP110 and CPAP 
(16). In parallel to the elongation, many different proteins are assembled in high order into a 
growing PCM.  
 
      The PCM protein pericentrin (PCNT) plays a central role in organizing the assembly, 
which is essential to provide mature centrosomes with the capacity to nucleate many 
microtubules during mitosis (17). When both centrosomes are fully assembled, they break 
apart at the G2/M-transition (disengagement) with the help of PLK1 and Separase (103,118), 
and each centrosome moves towards one side of the condensed chromosomes — followed 
by the microtubules nucleation by γ-tubulin ring complexes (γ-TuRC), which later on will serve 
as spindles during mitosis to pull apart the sister chromatids. After cytokinesis, typically one 
centrosome with former mother and daughter centriole is now loosely attached by a flexible 
linker which remains in each daughter cell, and the cycle can restart once again (Figure 2.2) 












2.3 Centrosome in cancer and inherited diseases  
 
      A century ago, the German biologist Theodor Boveri hypothesized that increased 
centrosome numbers could drive tumorigenesis (3). This hypothesis is currently supported by 
evidence demonstrating that centrosome amplification (CA) is found in precursor lesions and 
could initiate events in carcinogenesis (18, 19). Additionally, CA is a well-known hallmark in 
around 10% of all human cancers (20, 21). Without a doubt, CA is existent in a wide range of 
both hematopoietic and solid cancer (Figure 2.3), these defects have been noticed in early 
and advance cancer development, and they were associated with poor clinical outcome and 
progressive tumor grade (30). 
 
      In many cases, CA can raise by two mechanisms; one is by centriole over-duplication 
and the second by cell doubling events (e.g., cytokinesis failure or cell-cell fusion). As a result 
of CA, cells with supernumerary centrosomes generate genetic diversity through asymmetric 
cell divisions on abnormal spindles with chromosome miss-aggregation (22, 23). 
Correspondingly, CA highly correlates with aneuploidy and chromosomal instability in cancer, 
leading to enhance cancer invasiveness through the disruption of cell-cell contacts and 
altering the position and size of cell-cell junctions, through increasing the activity of Rac1 and 
Rho GTPases (21, 24).  
 
      PLK4 is one of the master regulators of centriole duplication, which, when 
overexpressed, can induce CA, among others, through the generation of multiple procentrioles 
(25, 26). Overexpression of SAS6 (12), STIL (27), and pericentrin (28) can also result in over-
duplication of centrioles, which they might contribute to tumorigenesis yet need to be further 
explored. The overexpression of several centrosome components enhances cancer migration 
(29). PLK4 is known to be overexpressed in breast, lung, and colorectal cancer and correlates 
with not only worse outcomes but also predicts resistance to chemotherapeutic drugs (Figure 
2.3) (30). All of this makes targeting centrosome components known to play a part in 



























Figure 2.3: Relation between centrosome amplification (CA) and its consequences in cancer. 
(A-B) Centrosome abnormities are connected to several kinds of cancer: Solid cancer as well as 
hematological cancer. The percentage represents the CA-percentage within each cancer species. The 
figures are modified from (Chan, J.Y, 2011) (20). (C) One of the hallmarks of cancer is centrosome 
amplification. The obtained extra copy of centrosomes can control the fate of the cell and change the 
type of cancer behavior (111).   
 
 
      Centrosome abnormalities are not only connected to cancer. Cells with centrosomal 
defects suffer from a defective cell division, which is found to be especially crucial during 
neural development. Therefore, unbalanced centrosome numbers were postulated to cause 
cell death leading to intrauterine growth retardation, which could explain microcephaly (73). 
For instance, a genetically heterogeneous neurodevelopmental disorder known as  autosomal 
primary recessive microcephaly (MCPH) is caused by mutations in at least nine centrosomal 
genes such as; CEP152, CDK5RAP2, ASPM, CPAP, and STIL. MCPH is characterized by 
reduction in head circumference at birth and non-progressive mental retardation, which 
primarily affecting the size of the cerebral cortex; if the MCPH is associated with dwarfism, the 
syndrome is called microcephaly primordial dwarfism (PD).  PD defines as group of autosomal 
recessive human genetic disorders includes; Seckel syndrome, microcephalic 








diseases of this group.  PD paitents suffer from pre- and postnatal growth failure accompanied 
by microcephaly (31-34). Interestingly, such syndromes can emerge from mutations in 
centrosomal components, including PLK4, CEP152, PCNT, and many others, or ATR/ATRIP 
(linked to replicative stress). Although not much evidence was found on higher cancer 
prevalence in patients with Seckel syndrome, patient cells show chromosomal instabilities, a 
hallmark of many cancer cells (31- 34).  
 
2.4 Chromosomal instability is a hallmark of cancer 
 
      Chromosomal instability (CIN) is a hallmark of many human diseases like cancer, 
neurodegenerative diseases, and age-related diseases. CIN, as shown in many recent 
publications, can cause structural and numerical chromosome abnormalities (69, 70). As 
oncogene-induced replication stress or poor replication fork maintenance is an essential driver 
of genomic instability, also centrosomes abnormalities such as having excessive 
centrosomes, caused by hyper amplification can induce CIN is when the (31) (Figure 2.4). 
 
      The mechanisms behind the induction of centriole amplification are not fully described 
yet, but since it is found in many cancers at early stages, targeting this process would 
represent an attractive drug approach (20). Multiple centrosomes would propose multipolar 
mitotic divisions leading to severe aneuploidy and cell death in normal cell conditions. 
Unfortunately, this is not the case in cancer because cancer cells have found a way to 
overcome aneuploidy. One way in which cancer cells can avoid lethal aneuploidy is by 
clustering their centrosomes; a mechanism was first described by (Ring et al. 1982), in which 
cancer cells ensure bipolar spindle formation during mitosis despite multiple centrosomes, and 
thus cancer cells rely on this process for survival. Interestingly, defects in the clustering of 

































Figure 2.4: The hallmarks of cancer. Modified schematic representation of the hallmarks of cancer 
adapted from Hanahan et al., 2011. Chromosomal abnormalities leading to genomic instability and 
increasing the mutation rate in the cell is one of the main hallmarks of cancer. 
 
      In summary, cancer cells with clustered centrosomes were found to result in higher 
rates of CIN, partly because of mitotic kinetochore attachments and lagging anaphase 
chromosomes, which could promote tumorigenesis (31). 
 
  
2.5 Cell cycle and cancer  
 
      Actively dividing cells go through a series of events that are collectively known as the 
cell cycle. As a survival mechanism, cells need to replicate their genetic material during this 
cycle. However, cell cycle alternation is found in several kinds of diseases, and for such 
reason, the cell cycle is considered to be one of the most critical processes within our body. 
In healthy cells, the cell cycle is controlled by several checkpoints, and thereby the process is 






      Several proteins and checkpoints are required to ensure a faithful cell division and to 
overcome the obstacles that dividing cells may face during the cell cycle (35). The primary 
purpose of several checkpoints within the cell cycle is to guarantee that damaged or 
incomplete DNA is not being passed on to the newly born daughter cells. There are three main 
checkpoints within the cell: G1/S, G2/M, and the spindle assembly checkpoint (35). 
 
      The cell uses the G1/S checkpoint to make sure that it has enough raw materials to 
replicate its DNA fully. G2/M is another checkpoint which guarantees that the cell has enough 
cytoplasmic phospholipids for the newly born cells. Besides, cells check for unreplicated or 
damaged DNA after the S-phase and before they undergo mitosis (Figure 2.2) (36). Finally, 
the mitotic checkpoint is responsible for checking the spindle that has been formed and 
attached to the condensed chromosomes, and that all chromosomes are aligned before the 
onset of anaphase (35, 36).  
 
 
2.6 DNA replication in cancer  
 
      In dividing cells, beside centrosome duplication also DNA replication is required in 
every cell cycle. DNA replication must reach maturity before the onset of mitosis to ensure 
that upon cytokinesis, each daughter cell inherits a complete set of genes (37, 38). Replication 
is a highly regulated process, and any condition that compromises it is referred to as 
replication stress. Replication stress can arise as a result of several factors. Generally 
speaking, it can occur due to DNA lesions, diminished expression of replication factors, or a 
shortage in nucleotides. Also, replicative stress can be caused due to the expression of 
several oncogenes, for instance, RAS, HPV E6/E7, and cyclin E.  
 
      Both faithful chromosome segregation during M-phase and accurate DNA replication 
during S-phase are the two main requirements for the cell to maintain genome integrity and 
avoid genome instability (39). Therefore, the process of replication is a prerequisite of life that 
is tightly regulated (40). For that reason, several mechanisms have evolved to ensure error-
free copying, to repair potential mistakes, to stop cell division, and to drive faulty replicated 
cells into apoptosis (41). Some of which these mechanisms are; the contribution of the DNA 
polymerase in nucleotide selection and proofreading, mismatch repair mechanism, which 
comes to correct what the proofreading mechanism failed to fix and managing the balanced 
supply of nucleotides (41). As DNA replication is a very delicate process, if it is disturbed by 





Replication stress is not a common feature of healthy cells but is a significant cause of genome 
instability and linked to aberrant and tumor cells. Several mechanisms can explain the 
occurrence of this phenomenon in various kinds of cancers. Initially, replicative stress is 
induced after the activation of several oncogenes, which alter the replication timing and 
progression (38, 42). One more reason beyond the initiation of replicative stress in cancer is 
when the DNA damage checkpoint is not able to recognize the abnormalities on the DNA fork 
anymore and fails to protect the stalled forks and to restart replication progression through the 
activation of dormant replication origins (42). Together with dysfunctions of the DNA damage 
checkpoint, replicative stress can also be induced by dysfunction in DNA repair mechanisms, 
which upon DNA breaks are needed to repair the damage and prevent the fork from being 
stalled (38, 42). Reactive oxygen species (ROS) or misincorporated nucleotides are also 
sources of stressors that cause DNA lesions and can induce replicative stress (43). If the 
replication fork cannot continue proceeding along the DNA strand due to damage-induced 
obstacles, it stalls, whereas helicases usually progress to unwind the DNA helix and thereby 
to expose large areas of single-stranded DNA (ssDNA) (44). A stalling DNA replication fork 
activates the DNA damage response (DDR), a complex signaling cascade involving central 
mediators such as the kinases ATR and ATM, as well as their targets, the checkpoint kinases 
CHK1 and CHK2. Upon DNA damage, ATR is first recruited to the site of damage by f 
replication protein A (RPA), which covers ssDNA, following phosphorylation of its targets, i.e., 
CHK1 and Histone 2A.X. Subsequently, DDR signaling can mediate cell cycle arrest so that 
DNA replication errors and lesions will be repaired. When DNA damage becomes so severe 
that double-strand breaks occur, ATM-CHK2-signaling is activated, often leading to cell death 
to protect the whole organism from accumulating DNA errors (45). Cancer cells often display 
high levels of replicative stress and genomic instability because their accumulated mutations 
promote proliferation despite the lack of checkpoints and DNA repair systems (38). 
      
2.7 Seckel syndrome, a shared disease between centrosome abnormalities and 
ATR mutation 
 
      Besides cancer, Seckel syndrome is a well-known genetic condition characterized by 
the accumulation of replicative stress through a mutation in ATR or its interacting protein 
ATRIP. While the loss of function mutations of ATR/ATRIP were found to be embryonically 
lethal (46), hypomorphic mutations resulting in reduced protein levels clinically caused by 
Seckel syndrome (47, 48). Seckel syndrome can be mimicked by a genetic mouse model 
harboring a comparable ATR mutation and showing signs of Seckel syndrome (49). Seckel 
syndrome (SCKL/SCKS) is a rare genetic disorder yet well-characterized disease that belongs 





spectrum disorders (50). Patients of Seckel syndrome suffer from primordial dwarfism, 
microcephaly, a sloping forehead, and beaked nose, which is why the condition is also called 
"bird-headed dwarfism." In some cases, patients are mentally disabled due to their 
underdeveloped brain, and their body is of short stature, while most organs developed to 
normal function (32, 50). 
 
What is more intriguing about this disease is that mutations cause the majority of 
clinical Seckel syndrome cases in ATR/ATRIP, but also in the centrosomal protein 152 
(CEP152; SCKL5), identified by Kalay, E. et al. (Figure 2.5) (32). In centrosomes, Cep152 is 
a scaffold protein localized in the PCM. Besides its functional involvement in centriole 
duplication, where it is responsible for the recruitment of PLK4 to the centrosome site, CEP152 
was identified as a "genome maintenance protein." One of the studies that looked at patient 
fibroblasts harboring a homozygous splice donor-site mutation revealed that loss of CEP152 
protein function caused centrosomal and mitotic aberrations. Most strikingly, the authors also 
observed increased phosphorylation of histone 2A (γ-H2A.X), which is a marker for replicative 
stress induced by ATR-dependent DDR, in CEP152 Seckel fibroblasts, proposing a function 
of CEP152 in protecting genomic integrity (32). Mutated CEP152 has also been identified in 
primary autosomal-recessive microcephaly (MCPH9; 51), characterized by small brain size 
and mental retardation, but standard height. Other types of Seckel syndrome and primary 
microcephalia have also been attributed to mutated centrosomal components: Cep152-
interacting protein Cep63 (SCKL6; 52), Microcephalin 1 (MCPH1), CEP135 (MCPH8), 
CDK5RAP2 (MCPH3), CPAP/CENPJ (MCPH6/ SCKL4) and others (50). Besides, more 
proteins that are essential for the duplication of centrosomes were found to be mutated in 
different types of microcephaly: Spindle assembly abnormal protein 6 (SASS6; MCPH14) and 
Polo-like kinase 4 (PLK4) (53). Additionally, mutations in the centrosomal pericentrin (PCNT) 
cause Seckel syndrome (54) as well as microcephalic osteodysplastic primordial dwarfism 










Figure 2.5: The role of centrosomes in development and disease. The phenotype of a 
PLK4-Seckel patient (a–b) Frontal and lateral view of a PLK4-Seckel patient. (c) Picture 






      Thus, both the loss of centrosomal proteins and a mutation in proteins related to DDR 
result in similar developmental defects.  
 
2.8 Oncogene-induced DNA replication 
 
     DNA replication must be tightly regulated during each cell cycle (41). Our genome is facing 
many intrinsic and extrinsic risk factors that interfere with DNA replication processes (45). One 
of these factors is the activation of one or more oncogene. Oncogenic activation is affecting 
DNA replication in which the DNA replication fork progression will be halted by either slowing 
it down or stalling it during the S-phase, leading the fork to collapse into DNA double-strand 
breaks, as well as incomplete sister chromatid separation (56). Oncogenic activation and DNA 
replicative stress promote chromosomal instability, which is a marker of tumor cells (56). 
      The activation of one of these oncogenes such as RAS, CDC25A, MYC, or CYCLIN E 
is sufficient to induce DNA replicative stress (57, 58). The oncogenes, as mentioned above, 
are considered as growth factors that stimulate cell proliferation. Initially, it was shown that the 
activation of CYCLIN E is responsible for increased cell proliferation by accelerating the entry 
to S-phase, leading to an increase in DNA replication initiation, which eventually causes 
replicative stress (57, 58). However, increasing cell proliferation by shortening the G1 phase 
is not the only mechanism of oncogene inducing replicative stress. The activation of 
oncogenes can activate the cell cycle also through the activation of transcription processes 
(59). The activation of transcription is mainly caused by the activation of RAS and MYC 
oncogenes (59). The activation of RAS oncogene stimulates the transcription through the 
extracellular-signal-regulated kinases (ERK), which in turn activates several transcription 
factors such as TBP, TIFIIIB, UBTF, and TIFIA (59). In contrast, the activation of the other 
oncogene MYC promotes transcription by activating the three RNA polymerases (59). 
However, the legitimate question at the moment is: How does the activation of transcription 
lead to DNA replicative stress? 
      Previously, it was shown that the activation of the transcription machinery has the 
potential to cause replication stress and fork collapse as well as genomic instability, which can 
be due to two reasons. Firstly, the mechanisms of transcription and replication are competing 
over the same DNA template in a similar affinity so that the active proteins may directly collide. 
Secondly, the formation of what is known as RNA: DNA hybrids (R-Loops) is another crucial 







2.9 Replication-transcription conflicts  
 
      Both transcription and replication occur at a high frequency within cells and, therefore, 
are required to be completed with high fidelity to conserve genetic information and cell 
functionality (60). As described in sections 2.5 and 2.6, our DNA is packed into chromatin, 
meaning it needs to be unwinded and separated into two DNA single strands before being 
replicated or transcribed. Both polymerases, DNA and RNA, need to act in coordination with 
several enzymes and factors, such as helicases to open up the double-stranded DNA and 
topoisomerases that are required to solve the DNA topology (61, 62). The DNA replication 
machinery is assembled at precise genomic locations, called the origin of replication, while 
the transcription complex is assembled on areas called promoters. Both can move for many 
kb and polymerize in the direction of 5'-3' before the termination occurs. During DNA synthesis, 
one replisome replicating the leading strand while the other is replicating the lagging strand. 
While, during transcription, several RNA polymerases transcribe one strand of the opened 
DNA while the other strand remains as ssDNA. Therefore, the competition over the same DNA 
template increases the chance of both processes to interfere with each other (Figure 2.6) (61, 
62). 
 
      A conflict that might arise due to the interference between DNA replication and 
transcription can lead to DNA damage and, eventually, genomic instability. The main reason 
behind such a conflict is the fact that these two abundant mechanisms are sharing the same 
DNA template. Unscheduled replication–transcription conflicts change the gene transcription 
program and generate replication stress, reducing fork speed (62).  
 
      On the other hand, cells have evolved numerous processes to reduce such conflicts 
and to rescue any replication fork that suffers from damage during conflicts for example 
Auxiliary Helicases, which their activities may assist the replisome dislodge transcription 
complexes ahead of the replication fork, in addition the S-phase checkpoint controls and 
responds to replication forks stalled at transcription complexes, by either controlling the tRNA 
gene transcription which reduces the interference with replication or by the activation of 
Mec1/ATR kinase followed by the phosphorylation of the nucleoporin Mlp1 which promotes 
fork progression by lowering the topological tension (136). However, the main question is: 
How can these two processes cope together, and how are conflicts between them being 
regulated? 
 
      During transcription and replication, chromatin structure is being disrupted to allow the 





strands DNA (63). As transcription-replication machineries share the same DNA template, 
they might meet head-on (65), which may lead to a collision between them. One main 
pathological result of replication–transcription collisions is the formation of stable RNA:DNA 
hybrids known as R-loops, which also displace a naked ssDNA (60).  
 
      An extended RNA:DNA hybrid model suggests that the RNA:DNA hybrids could be the 
result of an extension of eight-base pair (bp) RNA:DNA hybrid (66) within the transcription 
bubble as RNA-Polymerase II (Pol II) elongates. R-loop structurs are mostly generated by Pol 
II, transcribing a C-rich DNA template so that a G-rich transcript is produced. R-loops 
generation within the cells depends mainly on three features: high density of guanine, negative 
supercoiling, and DNA nicks (66).  
 
      R-loop formation can lead to a slowing or collapse of the replication fork leading to 
genomic instability (67, 68). The resolution of this RNA: DNA hybrids depends on specific 















Figure 2.6: Consequences of replication-transcription conflict. Schematic representation of 
head-on collision between replication and transcription machinery. Raised conflict will lead to 
pervasive R-loop formation.  
 
2.10 Crosstalk between centrosome duplication and DNA replication 
 
      Both processes of DNA replication and centrosome duplication need to be accurate. 





more relevant under stressed conditions. Consequently, we propose that replicative stress 
influences centrosomal components, and inversely the integrity of centrosomes promotes 
successful DNA replication. 
 
      Accumulating evidence suggests that proteins of the DDR signaling, induced upon 
replicative stress, are involved in centrosomal processes. The checkpoint kinase CHK1 was 
shown to mediate centrosome amplification after ionizing radiation of human cells (74, 75). 
CHK1 was postulated to shuttle between centrosomes and nuclear localization to sites of DNA 
damage and to be partially activated at the centrosome. More in-depth analysis revealed that 
DNA damage caused an expansion of PCM through the activity of CHK1 in the nucleus is due 
to control the DNA damage response (DDRs), which was supported by the PCM-component 
pericentrin (PCNT), and diminished through microcephalin (MCPH) (76). 
 
      For PCNT mutations in Seckel syndrome, it was found that ATR-dependent signaling 
upon DNA damage, mediated through CHK1, is defective in patient cells, which display similar 
characteristics to ATR-mutated Seckel cells (54). Thus, CHK1-ATR signaling seems to play 
an essential role in connecting the DDR and centrosome integrity. 
 
       Related kinases, CHK2 and MAPK-activated protein kinase 2 (MK2), partially localize 
to the centrosome as well, and CHK2 has even been found to be directly phosphorylated by 
PLK4 at centrosomes (77). Additionally, the tumor suppressor p53, which we have elucidated 
to support the progression of DNA replication forks (78), is partially localized to centrosomes 
and is proposed to regulate centriole duplication (79). 
 
       Intriguingly, loss, as well as amplification of centrosomes, triggered a p53-response 
(73), whereas p53 depletion caused centriole over-duplication (80). Therefore, several 
proteins have been identified with dual localization at centrosomes and on DNA. Indeed, it’s 
also intriguing to investigate and fully discover those proteins which have potential crosstalk 
between DNA replication and centrosome assembly. 
 
       Centrosome abnormalities and replication stress are commonly observed features of 
cancer cells and critical drivers of genomic instability giving rise to human diseases, such as 
cancer or developmental and inherited diseases. Replication stress induces several signaling 
cascades that enhance ATR and CHK1 activity, which in turn enhances the processivity of 
replication forks despite all stressors in the surrounding environment (46-49). In addition, a 
hypomorphic allele of ATR and its partner ATRIP can give rise to a rare yet well-defined 





SCKL4, 5, 6 are caused by a mutation in some of the centrosomal components such as 
CENPJ, CEP152, and CEP63, respectively (46-49). Altogether, this might suggest that DNA 






3. PROJECT AIM 
 
 
       Our main aim in this project is to understand how the integrity of centrosomes can affect 
DNA replication, to further understand the interdependence of replication stress and 
centrosomal integrity during S-phase. We want to reveal whether there is any potential 
crosstalk between the two main types of duplication during the cell cycle: DNA replication and 
centrosomes duplication. Furthermore, we are interested in clarifying the leading players which 
are responsible for such an effect. 
 
How do deficiencies in centrosomal composition lead to replicative stress? This central 
question can be further subdivided into smaller ones, such as the following. 
 
i. What characteristics of DNA replication are compromised by centrosome disruption? 
 
ii. What is the underlying mechanism behind the observed effect? 
 
iii. How is MK2 activated upon centrosome disruption? 
 
iv. Which downstream component(s) of the P38-MK2 pathway is activated by centrosome 
disruption? 
 
v. Which component(s) of the pathway, if any, are located at the centrosome? 
 
vi. Finally, how do PLK4 overexpression and supernumerary centrosomes affect DNA 
replication?





4. MATERIALS AND METHODS 
 
i. Technical devices 
 
 





Centrifuge 5415R Eppendorf 
Centrifuge 5810R Eppendorf 
Chemiluminescence imager Chemocam HR 16 3200 Intas Science Imaging Instruments 
Chemiluminescence imager Chemidoc XRS+ Biorad 
Electrophoresis system for SDS-PAGE Amersham Biosciences 
Laminar flow cabinet Hera safe Heraeus, Thermo Scientific 
Light microscope Axovert 40C Zeiss 
Microscope,  Axio Scope.A1 Zeiss 
PCR machine Thermocycler T Personal Biometra 
pH meter inoLab WTW GmbH 
Pipets, Eppendorf Research Eppendorf 
Power Supply Biometra 
Roller RM5-30V CAT 
Scales Acculab ALC-6100.1 Sartorius 
Scales LE623S Sartorius 
Scanner CanoScan 8600F Canon 
Sonication device Bioruptor Diagenode 
Spectrophotometer NanoDrop ND-1000 PeqLab 
Thermomixer Comfort Eppendorf 
Vortex-Genie 2 Scientific Instruments 
FACS BD FACSCanto II 
FACS GuavaEasy Cyte Plus 
 









96-well plate for qPCR 
 
4titude 
Cell culture dishes (10cm, 15cm) Greiner 
Bacteria culture dish (10cm) Sarstedt 
Cell culture plate (6-well, 12-well) Greiner 
Cell culture plate 24-well Costar 
Cell scraper (16cm, 25cm) Sarstedt 
Coverslips Menzel, Roth 
Cryo-tubes for cell freezing Nunc 
Glass pipets (5ml, 10ml, 25ml) Sarstedt 
Glass Slides Superfrost Menzel 
Parafilm Sigma-Aldrich 
Pipet tips (10 μL, 20-200 μL, 1,000 μL) Greiner 
Protran nitrocellulose transfer membrane Whatman 
Reaction tube (0.5 mL, 1.5 mL, 2.0 mL) Eppendorf 
Reaction tube (15 mL, 50 mL) Greiner 
Safe-lock reaction tube (1.5 mL) Eppendorf 
Sterile filter (0.2μM and 0.45μM) Millipore 
Syringe canula  B.Braun 
Whatman paper Whatman 









Acetic acid Roth 
Agar Sigma-Aldrich 
Agarose Roth 
Albumin Fraction V (Bovine Serum Albumin, BSA) Roth 
Ammonium persulfate (APS) Roth 
Ampicillin Roth 
Chlorodeoxyuridine (CldU) Sigma-Aldrich 
Chloroform Roth 
Deoxynucleotide triphosphates (dNTPs) Primetech 
Dimethyl sulfoxide (DMSO) AppliChem 
DNA ladder GeneRuler Fermentas 
Ethanol 99.8% Roth 
Formaldehyde, 37% solution Roth 
Glycerol >99% p.a. Roth 
Glycine >99% p.a. Roth 
Hydrogen chloride (HCl) Roth 
Iododeoxyuridine (IdU) Sigma-Aldrich 
Isopropanol Roth 
Lipofectamine 2000/3000 Invitrogen 
Methanol >99% (MetOH) Roth 
Milk powder Roth 
Nailpolish essence 
Nuclease-free H2O Ambion 





PageRuler Prestained Protein Ladder Fermentas 
Pefablock SC protease inhibitor Roth 
Pepstatin A AppliChem 
Ponceau S Roth 
Potassium Chloride AppliChem 
Potassium Hydrogenphosphate (KH2PO4) Roth 
Random hexamer primers Thermo Scientific 
Rotiphorese Gel 30 Roth 
Sodium (di-)hydrogenphosphate dihydrate (Na2HPO4) x 2H2O Roth 
Sodium chloride (NaCl) Roth 
Sodium deoxycholate AppliChem 
Sodium dodecyl sulfate (SDS) Roth 
Sodium dodecyl sulfate (SDS) BioRad 
Sodium ethylene diamine tetra-acetic acid (Na-EDTA) Roth 
Sodium hydrogen phosphate monohydrate (NaHPO4 x H2O) Roth 
Sodium hydroxide (NaOH) Sigma-Aldrich 
SYBR green Invitrogen 
Tetramethylethylenediamine (TEMED) Merck 
Trehalose dehydrate USB Corp. 
Trisamine (Tris) Pufferan >99% p.a. Roth 
Triton-X100 AppliChem 
TRIZOL Invitrogen 
Tween 20 Applichem 

































in PBS pH 7.4  
  
  





Acetic Acid 25% 
  
  
Fibre Assay Spreading Buffer 
 




SDS  in ddH2O 0.5% 
  
  
6x Laemmli Buffer 
 






bromophenol blue 0.02% 
in ddH2O  
  
  






Na2HPO4 x 7H2O 0.81mM 
KH2PO4 0.15mM 
in ddH2O  







acetic acid 1% 
in ddH2O  
  
  








Tris, pH 7.5 20mM 
in ddH2O  
  
  







in ddH2O  
  
  








in ddH2O  
  
  





glycin  192mM 
MeOH 20% 
in ddH2O  
  
 




0.1 M  
EDTA 1 mM  
EGTA 0.5 mM  






























v. Enzymes and reaction buffers 
 
 
Enzyme Buffer Producer 
M-MuLV reverse transcriptase 10x MuLV buffer New England Biolabs (NEB) 
Taq DNA Polymerase for qPCR 
 
10x Taq buffer (+KCl, -








Immobilon Western HRP Substrate Peroxide Solution Millipore, Merck 
Pierce BCA Protein assay kit Thermo Fisher 
PureYield Plasmid Midiprep System Promega 
SuperSignal Western Femto Maximum Sensitivity Substrate  Thermo Fisher 









EDTA 10 mM  
EGTA 0.5 mM  
HEPES 20 mM  




0.15 M  
EDTA 1 mM  
EGTA 0.5 mM  
HEPES 50 mM  






NaCl 0.75 M  
EDTA 5 mM  
EGTA 2.5 mM  





















U0126 Inhibitor Cell signaling  
CFI-400945 Cayman chemical  
Thymidine 
Sigma 
PD 0332991 isethionate (CDK4i) Sigma 
LDC00003 –CDK9 I Selleckchem 
Dimethylenastron DME  Sigma 






  siRNA  Manufacturer  Identifier  
 
  Silencer select negative control #1 
 







Silencer Select siRNA Cep152-1  
Silencer Select siRNA Cep152-2  











   
Silencer Select siRNA CCP110-1 
 
Silencer Select siRNA CCP110-2 
 















Silencer Select siRNA SASS6-1 
 
Silencer Select siRNA SASS6-2 
 












Silencer Select siRNA CEP192-1 
 
Silencer Select siRNA CEP192-2 
 









Silencer Select siRNA MK2_1 
 
Silencer Select siRNA MK2_2 
 












Silencer Select siRNA CJUN-1 
 
Silencer Select siRNA CJUN-2 
 












Silencer Select siRNA MAP3K11 -1  
Silencer Select siRNA MAP3K11 -2 
 






































Name Source Identifier 











pFRT_TO_DESTFLAGHA was a 




pcDNA3 Plk4(Sak) wt (Nigg 
HR9) 
pcDNA3 Plk4(Sak) wt (Nigg HR9) 











Antibody Source Identifier 
 
Anti-Pericentrin antibody [mAbcam 











phospho-H2A.X (Ser139) clone 20E3 
rabbit 
Cell Signaling 9718 
Phospho-HSP27 (Ser82) Antibody Cell Signalling 2401L 
p38 MAPK Antibody  Cell Signalling 9212S 
ATF2 Antibody (F2BR-1) Santa Cruz sc-242 
MAPKAPK-2 Antibody  
 




Cell signaling 3007S 





rat anti-BrdU [BU1/75 (ICR1)] – no 
longer available 
AbD Serotec MCA2060 (AB_323427) 
rat anti-BrdU [BU1/75 (ICR1)] Abcam ab6326 (AB_305426) 
mouse anti-BrdU clone B44 BD-Bioscience 347580 (AB_10015219) 
Alexa Fluor 488-conjugated goat anti-
rat antibody 
ThermoFisher A11029 (AB_138404) 
Alexa Fluor 555-conjugated goat anti-
rat antibody 
ThermoFisher A21434 (AB_141733) 
S9.6 antibody 
 
Absolute antibody Ab01137-2.0 
 
Anti-MLK3 antibody [EP1460Y]  Abcam ab51068 
RNAseH1 Antibody Abcam ab56560 
PLK4 antibody Proteintech 12952-1-AP 
RNA Polymerase II (N-20)  SantaCruz sc-899  
Phospho-ATF-2 (Thr71) Antibody  Cell Signaling 9221S 
c-Jun Abcam ab32137 
 
P-c-Jun (S63) Cell Signaling 9261 
Hsc70 (B-6) Santa Cruz sc-7298 
Histone H3 Abcam ab1791 
Histone H3 (acetyl K27) Abcam ab4729 
MCM7 (D10A11) XP Cell Signaling 3735 
GAPDH (6C5) Abcam ab8245 
ssDNA MS X HU Merck 2684913 
 
 





xi. Secondary Antibodies for Western Blot 
 
 
Antibody Manufacturer      Catalog Number 
 
HRP-coupled AffiniPure F(ab')2 





HRP-coupled AffiniPure F(ab')2 
fragment, anti-rabbit IgG (H+L) 
Jackson Immunoresearch 715-036-150 
 
Alexa-Fluor-488 goat anti-mouse  
 




Alexa-Fluor-555 goat anti-mouse  
 




Alexa-Fluor-647 goat anti-mouse 
 

















Skin fibroblast -1 
Skin fibroblast-2 



















DMEM powder Gibco, Life Technologies 
FCS Gibco, Life Technologies 
L-glutamine Gibco, Life Technologies 
PBS (tablets) Gibco, Life Technologies 
Penicillin/Streptomycin Gibco, Life Technologies 
Puromycin Gibco, Life Technologies 
RPMI 1640 w Hepes w/o Glut Gibco, Life Technologies 
Tetracyclin Gibco, Life Technologies 




















Penicillin/Streptomycin (Pen/Strep) 50U/ml 
L-glutamine 200μM 
Ciprofloxacin 10μg/ml 















Penicillin/Streptomycin (Pen/Strep) 50U/ml 






Bacterial strains used for plasmid amplification 
 
 
Bacteria strain Source 
 



























GraphPad Prism GraphPad Software 
Image Lab 5.2.1 Biorad 
ImageJ General Public License 













2YT medium 100% 








i. Cell culture 
 
 
      Cells were cultivated at 37°C, 5% CO2. H1299, RPE-P53KO (WT-G12D) cells were 
cultured in DMEM (Dulbecco's Modified Eagle Medium) supplied with 10% FBS (fetal bovine 
serum), 2 mM penicillin, 2 mM streptomycin and 10 µg/mL ciprofloxacin. SW48 (WT-G12D, G13D, 
G12V) was cultured in Mayco’s medium supplied with 10% FBS (fetal bovine serum), 2 mM 
penicillin, and 2 mM streptomycin.  Seckel and fibroblast cells were cultivated with DMEM 
Glutamax 20% FBS (fetal bovine serum), 2 mM penicillin, 2 mM streptomycin, and 10 µg/mL 
ciprofloxacin. For cell, harvesting, cells were washed with pre-warmed PBS, followed by the 
addition of 0.1% trypsin/EDTA for 5 minutes at 37°C. Once cells detached, the reaction was 
stopped by the addition of the FCS-containing culture medium. Cells were either counted and re-
seeded again for experimental purposes or re-seeded at dilutions between 1:10 two times per 
week. Seckel cells and the fibroblast cell medium were changed every second day, and splitting 
was once a week. All cell culture work was carried out under sterile conditions.  
 
ii. Cell transfections 
 
 
      Knocking down gene expression in human cells, a reverse transfection of cationic 
liposome formulation Lipofectamine 3000 was performed. A transfection mix with a final 10nM 
concentration siRNA was prepared by separately incubating siRNA (Solution A) and 
Lipofectamine (Solution B) with DMEM without supplements. The two separate solutions were 
incubated at room temperature for 5 minutes. Solution B was added to solution A, followed by an 
additional 20-minute incubation. Cells were seeded with the transfection mix into medium 
containing supplements. Culture medium was exchanged after 24 hours, and experiments were 
carried out 48-72 hours post siRNA transfection. Overexpressing DNA plasmid, a forward 
transfection protocol was used according to the manufacturer’s instructions. For this, a 
transfection mix was prepared from 2μg of plasmid DNA (solution A) and a second mix containing 
Lipofectamine 2000 (solution B) in DMEM without supplements incubated for 5 minutes 
separately, then they were combined (solutions B & A) and incubated for 15 minutes. The 





transfection mix was added drop-wise onto adherent cells. Media was changed after 6-7 hours, 
and experiments carried out 30 hours post-transfection.  
 
iii. Chemical Treatments  
 
 
      Several pharmacological inhibitors used for cell treatments were dissolved either with 
DMSO or water and aliquots prepared according to the manufacturer’s instructions. Treatments 
were prepared by adding the drug to a pre-warmed medium. For control samples, the respective 
solvent was added instead of the drug. 
 
iv. Cell synchronization 
 
 
      The synchronization of H1299 cells at the G1/S transition was carried using the CDK4 
inhibitor and Thymidine. H1299 cells were treated with CDK4 inhibitor Palbociclib for 24 hours, 
followed with 500 nM Centrinone B for another 24 hours. CDK4 inhibitor was washed 16 hours 
prior harvesting and replaced by a thymidine block with Centrinone B. 48 hours after treating the 
cells with 500 nM Centrinone B. Cells were released by removing from Thymidine for 3-4 hours 
before harvesting. 
 
v. Flow cytometry 
 
 
      Cell cycle analysis was carried as described in Figure 6.3. Cells were treated as indicated 
in the previous section of cell synchronization and as in Figure 6.3.  Post-treatment cells were 
detached and fixed with cold ethanol at -20°C for overnight. Samples were centrifuged, and the 
pellet rehydrated with PBS for 10 minutes. After centrifugation, the cell pellet was resuspended in 
PBS with RNase A (200μg/ml) and incubated at 37°C for 30 minutes. Propidium iodide staining 
was performed with a 30μg/ml solution for 5-15 minutes at room temperature in the dark. Cells 
were analyzed using a Guava® Express Pro EasyCyte flow cytometer and Cyto Soft 5.3 software 
(Merck). Measurements were taken by counting 10000 events at 300-700 cells/mL. To determine 
the number of gated cells in each cell cycle phase (G1, S, and G2/M), histogram markers were 
adjusted to the asynchronous cell FACS profile. The average values of duplicates were 
determined for each cell cycle phase. 





vi. Cell proliferation assay (Celigo) 
 
      For confluence measurement, cells were seeded at a density of 5000-10000 cells/well in 
24-well plates. Cells were treated as indicated in Figures 6.4, 6.6 and 6.9. Their proliferation 
capacity was measured using the CeligoTM Cytometer (Nexcelom, software version 2.0). Cell 
confluence was measured every 24 hours for up to 7 days. Experiments were carried out in 2 
biological replicates, and with six technical; the average of those was plotted on a graph using 








vii. Proteins separation by SDS-PAGE  
 
      Proteins were separated according to their molecular sizes using SDS-PAGE (Sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. Equal amounts of protein samples were 
loaded and separated by 10% SDS-PAGE. Electrophoresis was carried out with a constant 
voltage of 80V for stacking and 100V for separation. Finally, samples were transferred onto the 
nitrocellulose membrane on ice for 2 hours at 100V.   
 
viii. Immunoblotting  
 
       Cells were harvested in protein lysis buffer with proteinase inhibitors (pepstatin, leupeptin 
hemisulfate, aprotinin). The samples were sonicated to disrupt DNA-protein complexes. Total 
protein concentration was measured using a Pierce BCA Protein assay kit (Thermo Scientific 
Fisher). After boiling the samples in Laemmli buffer at 95°C for 5 minutes, equal amounts of 
protein samples were separated by SDS-PAGE, transferred onto nitrocellulose, and incubated 
with primary antibodies of the following proteins: MLK3 (D-11) (Santa Cruz) , PLK4 (Proteintech), 
p-p38 (E-1) (Santa Cruz), p-MK2 (Cell signaling), pHsp27 S82 (Cell signaling), GAPDH (Abcam), 
RNAseH1 (Abcam), HSC70 (Santa Cruz), H3K27me3 (Abcam), H3K27ac (Abcam), Histone H3 
(Abcam), P-JUN (S63) (Cell signaling), JUN (Abcam), TBP (Santa Cruz), ATF2 (Santa Cruz), 
Parameter Meaning 
Intensity threshold 15 
Precision High 
Diameter 30 
Minimum thickness 3 





Phospho-ATF2 (T71) (Cell signaling), RNA Polymerase II (N-20) (Santa Cruz), MCM7 (D10A11) 
XP (Cell signaling), MAPKAPK-2 (Cell signaling), P53 (Cell signaling), phospho-H2A.X (Ser139) 
(Cell signaling). To visualize specific proteins on the membrane were incubated with secondary 
conjugation antibody to horseradish peroxidase (HRP). Protein level was visualized by the Intas 
ChemoStar Imager Software and the Image Lab 5.2.1 Software by Biorad.  
 
ix. RNA extraction and real-time quantitative PCR  
 
      Total RNA was extracted from cells using TRIzol® (Invitrogen). mRNA was prepared by 
reverse-transcribed using Moloney Murine Leukemia Virus reverse transcriptase and random 
hexamer primers (Thermo Scientific). qRT-PCR analysis using SYBR Green (Invitrogen) was 
followed. Gene expression levels were normalized to the mRNA encoding HPRT1 or 36B4, and 
the analysis was conducted using the ΔΔCt method. 
 
x. R-loop detection 
 
      Cells were grown on coverslips overnight prior to transfection / treatment, washed once 
with phosphate-buffered saline (PBS), and fixed either by cold methanol at -20C for 20 minute or 
with 4% paraformaldehyde for 10 minute at room temperature followed by permeabilization with 
0.5% Triton X-100 in PBS for 30 minute, three brief washes with PBS containing 0.1% Tween 20 
(PBST) and blocking with 3% bovine serum albumin (BSA) in PBST for 1 hour. The primary 
antibody S9.6 (Absolute antibody) was diluted in the blocking buffer (1:100) and incubated 
overnight at 4°C, followed by incubation with 488 Alexa Fluor-coupled donkey anti-mouse IgG 
(H+L) (Invitrogen) 1:250 for 2 hours at room temperature. Coverslips were washed with PBST 
and were briefly incubated with 1:2000 DAPI (4′, 6-diamidino-2-phenylindole), followed by 
mounting (DAKO). Fluorescence signals were detected by a microscope (Zeiss Axio Scope.A1) 
equipped with filters for 488nm, an EC Plan-Neofluar 100x oil objective, and an Axiocam 503 
color camera. Per condition, approximately 15- 20 images were taken with the AxioVision 
software and analyzed using ImageJ. 
xi. Immunofluorescence analysis of centrosomes 
 
      Two thousand cells were seeded on eight well chamber slides (Nunc/Thermo, cat 
#177445) overnight before treatment. Cells were treated with 300nM Centrinone B or DMSO for 
48 hours. The slide was washed carefully once with phosphate-buffered saline (PBS), fixed and 





stained as above. Antibodies were used as follows: 1:200 PCNT (Abcam), 1:50 CEP152 (Sigma), 
1:100 MLK3 (Abcam), 1:500 of 488 Alexa fluor Donkey anti-mouse, 1:500 594 Alexa fluor goat 
anti-rabbit, 1:2000 Hoechst 33342. 
xii. Chromatin fractionation  
 
      Cells were synchronized using the CDK4 inhibitor Palbociclib and released into a 
thymidine block as described in the synchronization sections (Figure 2A). Forty-eight hours after 
treating the cells with 500 nM Centrinone B, the cells were trypsinized and collected in 15ml tubes, 
washed twice with PBS, and centrifuged at 100g for 5 minutes. The pellets were resuspended in 
1 ml Buffer A (10mM HEPES, PH 7.9, 10mM KCL, 1.5mM MgCl2 0.34M Sucrose 10% Glycerol, 
1mM dithiothreitol, and protease inhibitors cocktails (COmplete Roche) and transferred into 1.5 
ml tubes. Triton X-100 was added to each tube to a final concentration of 0.1% and incubated on 
a rotating wheel for 15 minutes at 4°C. The tubes were centrifuged at 1300g for 5 minutes at 4°C. 
The supernatant (cytoplasmic fraction) was transferred to new tubes. The pellets were washed 
once with Buffer A and then further lysed with 250 μl modified RIPA buffer (1mM EDTA, 150mM 
NaCl, 0.1% Na-DOC, 1% NP-40, 50Mm Tris pH7.5, and protease inhibitors cocktails- COmplete 
Roche). 50U of benzonase (nuclease; Novagen) was added to the samples and incubated for 5-
10 minutes at room temperature. Samples were mixed by pipetting during the incubation time 
until they lost viscosity. Samples were diluted 1:3 with a modified RIPA buffer. The supernatant 
was cleared by centrifuging the samples for 7 minutes at 16000g, 4°C, and the clear chromatin 
fraction was transferred to a new tube. After boiling the samples in Laemmli buffer at 95°C for 5 
minutes, equal amounts of protein samples were separated by SDS-PAGE, transferred onto 
nitrocellulose, and visualized with the following antibodies: JUN (Santa Cruz), ATF2 (Cell 
signaling), MCM7 (Cell signaling), GAPDH (Abcam). 
xiii. EdU click reaction  
 
     Both synchronized and non-synchronized H1299 cells were treated with 500Nm were 
incubated with 10µM EdU two hours before harvesting cells. Two hours post labeling the cells 
medium was removed, and cells were washed with 1X PBS. Cells were fixed with 3.7% PFA in 
PBS for 30 minutes on RT.  Cells were permeabilizated with 0.5% Triton X-100 for 30 minutes on 
RT, followed by two times washes with PBS. Staining and detecting the EdU incorporation into 
DNA was detected using the Click-iT™ EdU Alexa Fluor® imaging kit (Invitrogen/Molecular 
Probes, Eugene, OR). 
 





xiv. Dot blot analysis of RNA: DNA hybrids 
 
      H1299 cells were synchronized, as in Figure 2A. Forty-eight hours after treating the cells 
with 500 nM Centrinone B or 2 hours with 5µM etoposide, the cells were fixed with 1.1% PFA in 
Buffer A for 30 minutes, followed by quenching with glycine. The cells were then harvested in 
Buffer B, then resuspended in Buffer C. 150µL 1X IB Buffer was added to the pellet. Samples 
were sonicated (Bioruptor, ten cycles, 30sec on, and 30sec off) and centrifugation, the 
supernatant was treated with proteinase K at 50°C for one hour, phenol-extracted and ethanol-
precipitated. 500ng of the DNA in 2 µL was spotted onto the pre-wet nitrocellulose membrane and 
cross-linked with UV-C. The membrane was blocked with 5% BSA in PBS-T (0.25% Tween-20) 
and incubated with S9.6 antibody (1:300 in 5% BSA in PBS-T) for 16 hours at 4°C, followed by 
secondary antibodies. For normalization and in parallel, the DNA was denatured with 2.5M HCl 
for 10 minutes, washed with PBS-T, and incubated with antibody to ssDNA (1:1000) followed by 
secondary antibody. The peroxidase-coupled secondary antibodies were detected by 
luminescence.  
xv. Chromosome spread analysis and chromosome counting 
 
      H1299 cells were seeded in 6-well plates, as in Figure 6.3. The following day, cells were 
treated with DMSO or Centrinone B and further incubated for two days or seven days. On the day 
of harvesting, cells were treated with 2 µM Dimethylenastron DME (Sigma) for 4.5 hours. The 
cells were then trypsinized and resolved in 750 µL hypotonic solution (40% medium in water) for 
10-15 minutes.  250 µL of Carnoy’s fixative solution (MeOH-glacial acetic acid (3:1)) was added 
to the pellet. The cells were then resuspended twice in Carnoy’s fixative and stored at -20 °C for 
16 hours. After resuspension in acetic acid, 10 µl of cell suspension was dropped on cold glass 
slides from ~ 2 m height. Slides were placed on a 42 °C heat block for ~ 10-15 minutes and then 
stained with 8% Giemsa solution for 15 minutes. The analysis of chromosomes was carried out 
by transmission microscopy. 
xvi. DNA Fiber Assay 
 
      DNA fiber assay was our way to study replication speed and progression in cells subjected 
to centrosomes impairment. The foremost step in this assay is the incorporation of two labeling 
pulses with the nucleoside analogs CldU and IdU; Jackson & Pombo, 1998. IdU and CIdU 
incorporation into newly replicated DNA provides a mark that can be used for immunostaining at 





a later stage. The following treated cells were incubated with CldU 50M for 20 minutes, followed 
by IdU, both from Sigma-Aldrich 25M for 60 minutes. After the labeling procedure, cells were 
harvested by washing them twice with ice-cold PBS followed by scraping them into 2ml cold PBS. 
Cell was centrifugated at 4°C and 5000 rpm for 5 minutes and resuspended to a final 
concentration of 500,000 cells per milliliter in cold PBS. Labeled cells were spread onto Superfrost 
glass slides by applying a 5µl drop of cell suspension on top of the slide and airdrying for about 2 
minutes. Cells were lysed by using DNA Fiber Spreading Buffer for 2 minutes at room 
temperature. The spreading step was carried by tilting the drop mixture of cells with lysis buffer 
slightly to run down slowly (about 3 cm/min) followed by air drying under a fume hood. Finally, the 
slides were fixed in a Fiber Assay Fixative solution for 10 minutes at room temperature before 
storage at 4°C for up to one month. 
 
      On the day of staining, fixed slides were rehydrated by incubating them with ddH2O once 
for 5 minutes and followed with acid treatment (2.5M HCl) to denature the double-strand DNA and 
obtain single-stranded DNA. After denaturing the double stands DNA, the samples were washed 
twice with PBS (adjusted to pH 7.4). Before immunostaining, the slides were blocked with a 3% 
BSA in PBS solution to avoid unspecific antibody binding for 60 minutes.  Primary antibodies that 
recognize CldU and IdU specifically were applied to dried slides in 250µl blocking solution with a 
1:400 dilution and incubated at 37°C for one hour. Samples were rinsed with PBS and fixed in a 
4% formaldehyde solution for 10 minutes. The slides were again rinsed with PBS and incubated 
with a blocking solution three times for 5 minutes. Fluorescently labelled secondary antibodies 
AlexaFluor488 goat-anti-mouse and AlexaFluor555 goat-anti-rat recognized primary antibodies 
from rat origin and were applied to dried slides in 250µl with a dilution of 1:200 and incubated for 
1.5 hours at room temperature. Final washing steps of rinsing once with PBS, washing twice with 
blocking solution for 5 minutes, rinsing with PBS and water were conducted before mounting with 
Vectashield mounting medium.  
xvii. Microscope analysis 
 
      Each slide was analyzed with an Axio Scope A1 microscope (Zeiss) with filters for 488 
and 555nm, an EC Plan-Neofluar 40x objective (Zeiss), and an Axio Cam MRc/503 camera 
(Zeiss). Ten to twenty images were taken from all parts of the slide and at least two slides per 
sample. 
 





      Measurements of fiber and label length, as well as their occurrence, was carried out using 
Image J and its cell counter plugin (Kurt de Vos, University of Sheffield, UK). All data were further 
processed using Microsoft Excel and GraphPad Prism.  
 
xviii. Statistical Analysis 
 
      Statistical analysis was carried out using the GraphPad Prism Software (Versions 6 and 
7). Analytical testing was performed using Graph Pad Prism 6 and 7. Mann-Whitney t-tests with 









6.1  The depletion of centrosomal components not only reduces DNA replication fork 
progression but also induces DNA damage and activates the stress response 
 
      To uncover whether centrosome integrity affects DNA replication, we sought to deplete several 
centrosome components using pooled siRNAs in H1299 cells. H1299 cells displayed a reduction in 
centrosome number upon depletion of several centrosome components (i.e., CEP192, CEP152, 
CCP110, and SAS6) (Figure 6.1 A-D) as well as a significant reduction in the corresponding mRNA levels 
(Figure 6.1 E). CEP192 localizes at the inner layer of the pericentriolar matrix, and it is crucial for the 
recruitment of pericentriolar material (PCM) (11). CEP152 is part of the outer PCM, and it is a critical 
protein for centrosome duplication through the recruitment of CDK2 to the site of centrosomes by forming 
a CEP152- CEP63-CDK5RAP2-WDR62 complex. It also acts as a scaffold protein that facilitates the 
interaction of PLK4 and CENPJ (10, 11). CCP110 is an additional centrosomal protein required for 
centrosome duplication but at a different stage of procentriole formation. CCP110 caps the mother 
centrioles and prevents cilia formation along with CEP97. 
 
      Additionally, CCP110 is required for correct spindle formation, regulating cytokinesis and, 
therefore, genomic stability. SAS6 is located at centrioles and is a centrosomal protein that plays a central 
role in the cartwheel assembly and ensuring the 9-fold symmetry. It is also necessary for centrosome 
duplication and biogenesis (14). Remarkably, each of these depletions significantly decreased fork 
progression in H1299 cells (Figure 6.1 F, G). 
 
       The induction of DNA damage in cells could be a reason behind the slower fork progression. 
Therefore, we intended to explore whether centrosome integrity can induce DNA damage; we firstly 
examined the accumulation of yH2AX as a marker of DNA damage in cells with altered centrosome 
number. In addition to the observed reduction in centrosomes number as well as slowing down the DNA 
fork progression upon depletion of centrosomal components, we also captured the increased yH2AX 
level (Figure 6.1 H, I). Searching for plausible activation of some stress-related markers, we managed to 
detect ATR/CHK1 phosphorylation (Figure 6.1 J). Thus, we conclude that the centrosome number is a 
























































































Figure 6.1: Depletion of centrosomal components interferes with DNA replication.  
(A) Centrosome disintegration upon depletion of centrosomal components. H1299 cells were transfected with siRNAs against CEP152, 
SASS6, CCP110, and CEP192 for 72 hours. Centrosomes were detected by indirect immunostaining of PCNT, and 4′,6-Diamidin-2-
phenylindol (DAPI) was used to outline the nuclei (scale bar = 20 μm).  
(B) Quantification of the centrosome signals per cell to DAPI-stained nuclei from A. 300 cells from A was quantified per condition and presented 
as a percentage using GraphPad Prism. ****P < 0.0001. 
(C) Similar to A, cells were treated with CEP152, SASS6 siRNA for 72 hours. Centrosomes were detected using an antibody against CEP152 
and 4′,6-Diamidin-2-phenylindol (DAPI) was used to outline the nuclei (scale bar = 20 μm). 
(D) Quantification of the centrosome signals per cell to DAPI-stained nuclei. One hundred fifty cells from C were quantified per condition and 
presented as percentage (the number of detectable centrosomes divided by the number of nuclei, multiplied by 100%) using GraphPad 
Prism. ****P < 0.0001. The results presented are an average of three biological replicates.  
(E) The efficiency of single siRNA-mediated depletion of centrosomal components. RNA was isolated 72 hours post siRNA transfection 
(CCP110, CEP192, CEP152, and SASS6), followed by reverse transcription and quantitative polymerase chain reaction (qPCR). The 
relative expression upon knockdown displayed normalized to control siRNA #1 and to the housekeeping gene HPRT1. Data represented 
is an average of n=3. 
(F) Schematic workflow of cells treated with siRNA. H1299 cells were depleted of endogenous CEP152, CCP110, CEP192, or SASS6 by 
siRNA transfection for 72 hours and then labeled with CldU (20 min) and IdU (60 min).  
(G) Compromised DNA replication fork progression upon centrosome depletion, as determined by DNA fiber assay. Cells were treated as in 
F followed by incubation with 5'-chloro-2'-deoxyuridine and iodo-deoxyuridine as indicated in panel I. Tracks of newly synthesized DNA 
were visualized by immunostaining of CldU (red) and IdU (green). Fork progression was determined through the length of the IdU label 
(kb/min). Two hundred fifty fibers were measured per condition per biological replicate and represented as a box plot. 
(H) Accumulation of yH2AX signal in cell depleting several centrosomal components. Cells were transfected with pool siRNA for 72 hours, 
followed by immunostaining against PCNT and the cell nuclei (DAPI) (scale bar = 20 μm).   
(I) Quantification of the yH2AX signal in cell nuclei upon centrosome depletion. The nuclear signal was quantified using the ImageJ software. 
The mean and distribution of three biological replicates (integrated) were calculated, and the significance was assessed using the Mann-
Whitney test.  
(J) Activation of ATR/CHK1 upon centrosome depletion. Lysates of H1299 cells were prepared 72 hours after depleting centrosomal 










6.2  Inhibiting PLK4 activity reduces cell proliferation, impairs DNA replication fork 
progression, and activates the stress response 
 
Polo-like Kinase 4 (PLK4) is another centrosomal protein that is being recruited to the site of 
centrosomes during the late G1-S phase by the scaffold protein CEP152. PLK4 is essential in the initiation 
step of centrosome duplication. A few inhibitors were developed to target this protein, which tends to be 
overexpressed in several cancer types, among which the small compound Centrinone B (108). Treating 
H1299 cells with 500 nM Centrinone B for 48 hours not only led to a substantial reduction in the number 
of detectable centrosomes (Figure 6.2 A-D), as described (108) but also impaired the progression of DNA 
replication forks (Figure 6.2 E, F). Moreover, we observed a global reduction of EdU incorporation (Figure 
6.2 G, H), indicative of replication stress, as well as a reduction in the cell proliferation rate (Figure 6.2 I). 
 
To assess DNA replication in this context, we performed fiber assays and measured the 
progression of single replication forks using several cell types. H1299 cells not only exhibited a 
substantially decreased fork progression in a highly significant manner, but also SW48 cells treated with 
Centrinone B displayed a reduction in the fork progression in a similar way to H1299 cells (Figure 6.2 J). 
Impairment of centrosomes appears to extend its impact to non-transformed cells. Our fiber assay shows 
the reduction in fork progression upon PLK4 inhibition in retinal pigment epithelial cells (RPEs) that were 
immortalized (but not transformed) by hTert (Figure 6.2 K). 
 
Moreover, it seems like the p53 status does not further compromise DNA replication and cell 
proliferation upon PLK4 inhibition. Fiber assay using HCT116 cell lines that do or do not contain functional 
copies of the TP53 gene showed a reduction in fork progression upon PLK4 inhibition as well as a 
decrease in centrosome numbers (Figure 6.2 L-N). Using a Celigo Imaging Cytometer, we observed a 
slowdown in cell proliferation as a consequence of PLK4 inhibition in H1299 as well as HCT116 cells 
(Figure 6.2 O, P). Additionally, we explored the possibility of induction of DNA damage under these 
conditions by assessing the accumulation of yH2AX as a marker of DNA damage in cells with impaired 
centrosome number. H1299 cells treated with Centrinone B showed an increase in yH2AX levels (Figure 
6.2 Q, R). The observed accumulation of yH2AX seems to be a result of the activation of the stress 
response pathway ATR/CHK1 (Figure 6.2 S). Thus, we conclude that PLK4 activity is indeed required to 





























































































































Figure 6.2: Inhibition of the centrosomal component PLK4 interferes with DNA replication.   
 
(A) Detection of centrosome disintegration upon PLK4 inhibition. Cells were treated with 500 nM Centrinone B for 48 hours. Centrosomes 
(immunostaining of PCNT) and the cell nuclei (DAPI) were detected (scale bar = 20 μm).  
(B) Quantification of the centrosome signals per cell to DAPI-stained nuclei. Upon centrosomes depletion, 300 cells were quantified per 
condition and presented as percentage (the number of detectable centrosomes divided by the number of nuclei, multiplied by 100%) 
using GraphPad Prism. (n=3), ****P < 0.0001. 
(C) Detection of centrosome disintegration upon PLK4 inhibition. Cells were treated with 500 nM Centrinone B for 48 hours. Centrosomes 
(immunostaining of CEP152) and the cell nuclei (DAPI) were detected (scale bar = 20 μm). 
(D) Quantification of the centrosome signals per cell to DAPI-stained nuclei. From C, 200 cells upon centrosomes depletion were 
quantified per condition and presented as percentage (the number of detectable centrosomes divided by the number of nuclei, 
multiplied by 100%) using GraphPad Prism. (n=3), ****P < 0.0001. 
(E) Schematic workflow of cells treated with Centrinone B. H1299 cells was treated with 500 nM Centrinone B for 48 hours and then 
labeled with CldU (20 min) and IdU (60 min). 
(F) DNA fiber assays detected reduced DNA replication fork progression in response to PLK4 inhibition in H1299 cells. Cells were treated 
as described in (A). Cells were treated with 500 nM Centrinone B for 48 hours, followed by incubation with 5'-chloro-2'-deoxyuridine 
and iodo-deoxyuridine as indicated in panel I. Tracks of newly synthesized DNA were visualized by immunostaining of CldU (red) and 
IdU (green). Fork progression was determined through the length of the IdU label (kb/min). Two hundred fifty fibers were measured 
per condition per biological replicate and represented as a box plot. 
(G) Representative images for the EdU incorporation signal in synchronized H1299 cells treated with 500 nM Centrinone B for 24-72 
hours. H1299 cells were treated with Centrinone B for 24-72 hours, and EdU incorporation was measured by click-it. 
(H) Quantification of images from (G). The signal was quantified using the ImageJ software. The mean and distribution of three biological 
replicates (integrated) was calculated, and the Mann-Whitney t-test assessed the significance. 
(I) Reduction in cell proliferation upon PLK4 inhibition with Centrinone B. 5*103 H1299 cells was seeded in each well of a 24-well plate. 
Cells were treated with DMSO or 300 nM Centrinone B. Cell proliferation capacity was measured using the CeligoTM Cytometer 
(Nexcelom, software version 2.0). Confluence was measured every 48 hours for ten days. The experiment was carried out in three 
biological replicates and six technical replicates for each time point. Note that most error bars are too narrow to be displayed.   
(J) Reduction in fork progression in SW48 cells after PLK4 inhibition. Cells were treated as described in F, followed by fiber assay. Two 







(K) Impact of PLK4 inhibition on non-transformed RPE-hTert cells. Cells were treated as described in F, followed by fiber assay. One 
hundred fifty fibers were measured per condition per biological replicate and represented as a box plot. 
(L) TP53 does not further compromise the fork progression in cells with impaired centrosomes. HCT116 cells that do or do not contain 
functional P53 gene were treated with 500 nM Centrinone B for 48 hours, then subjected to fiber assay. One hundred fifty fibers were 
measured per condition. 
(M) Detection of centrosome disintegration upon PLK4 inhibition. HCT116 cells deficient and proficient in P53 were treated with 500 nM 
Centrinone B for 48 hours. Centrosomes (immunostaining of PCNT) and the cell nuclei (DAPI) were detected (scale bar = 20 μm). 
(N) Quantification of centrosomes from I. Quantification of the centrosome signals per cell to DAPI-stained nuclei. One hundred fifty cells 
from A were quantified per condition and presented as percentage (the number of detectable centrosomes divided by the number of 
nuclei, multiplied by 100%) using GraphPad Prism. (n=3), ****P < 0.0001. 
(O) Inhibition of cell proliferation in HCT116-P53-/- upon PLK4 inhibition with Centrinone B. 5*103 in HCT116-P53-/- cells were seeded in 
each well of a 24-well plate. Cells were treated with DMSO or 300 nM Centrinone B. The experiment was carried out as described in 
L.  
(P) Cell proliferation inhibition in HCT116-P53+/+ upon PLK4 inhibition with Centrinone B. 5*103 in HCT116-P53+/+ cells were seeded in 
each well of a 24-well plate. Cells were treated with DMSO or 300 nM Centrinone B. The experiment was carried out as described in 
L.  
(Q) Accumulation of yH2AX signal in cells treated with PLK4 inhibitor. Cells were treated with 500 nM of Centrinone B for 48 hours, 
followed by immunostaining for PCNT and the cell nuclei (DAPI) (scale bar = 20 μm). 
(R) Quantification of the yH2AX signal in cell nuclei upon treatment with Centrinone B for 48 hours from A. The nuclear signal was 
quantified using the ImageJ software. The mean and distribution of three biological replicates (integrated) were calculated, and the 
Mann-Whitney test assessed the significance. 
(S) Activation of ATR and CHK1 upon PLK4 inhibition. H1299 cells were treated as described in Q, briefly with 500 nM Centrinone B for 






























6.3 PLK4 inhibition drives cells towards polyploidy   
 
Polyploidy is another source of DNA replication stress. It is known that centrosome abnormalities 
correlate with both numerical and structural chromosomal instability (CIN). Both high and insufficient 
levels of PLK4 are associated with abnormal spindle poles, uneven distribution of chromosomes, and 
numerical chromosomal abnormalities (4). However, it is still unknown to what extent inhibiting PLK4 
using Centrinone B has a direct impact on the spindle and to what extent DNA replication stress is 
involved. Therefore, we investigated the effect of long-term treatment with Centrinone B on the cell cycle 
as well as on chromosomal numbers. Interestingly, cell cycle and the chromosomal number remain the 
same after 48 hours, and only after seven days post-treatment an effect could be seen on both cell cycle 
as well as chromosomal number (Figure 6.3 A-C). In summary, our results suggest that DNA replicative 
stress is the immediate response to centrosomal depletion and that accumulation of replicative stress but 








































Figure 6.3: PLK4 inhibition leads to polyploidy after release.  
(A) Upper panel: Representative images of chromosome sets from three biological replicates. Cells were treated with 500 nM of 
Centrinone B or 10 nM of CFI-400945 for two to seven days, followed by spreading and visualizing chromosomes as indicated 
in material and methods. Chromosomes were stained with 8% Giemsa solution, and images were acquired by microscopy (100x, 
bright field mode). Lower panel: representative images of the cell cycle profile corresponding to the chromosomal spreading 
experiment. DNA content and thus, cell cycle distribution were assessed by propidium iodide (PI) staining and flow cytometry. 
(B) The number of chromosomes per cell was counted manually from A and plotted using GraphPad Prism (n=3 cells per time point 
and condition). 






6.4 Impairment of centrosomes causes replication stress independent of mitosis 
 
The results suggested that centrosomal integrity is required to maintain the processivity of 
DNA replication. However, it was not clear yet whether the observed effect on DNA progression is 
direct, or whether centrosome disruption first impairs chromosome segregation during mitosis, which 
might then reduce fork replication during the next S phase. The latter scenario was plausible for two 
reasons. Firstly, centrosome disruption indeed impairs the function of the mitotic spindle and thus 
chromosome segregation (121). Moreover, even one additional chromosome (numerical aneuploidy) 
is sufficient to trigger DNA replication stress (113). Therefore, we developed a strategy of disrupting 
centrosomes and assessing DNA replication without allowing the cells to go through mitosis during 
the time of centrosome impairment. The technical difficulty in doing so consisted of the prolongation 
of the period required to deplete centrosomal components – a minimum of 72 hours for siRNA 
knockdown or 48 hours for PLK4 inhibition. Therefore, we sought to arrest the cells in G1 for 48 hours 
to disrupt the centrosome during this time. Only after that, the cells were released to S phase but not 
allowed to reach mitosis. To do so, we first arrested the cells in G1, using the cyclin-dependent kinase 
4 (CDK4) inhibitor Palbociclib (122). As shown in (Figure 6.4 A), this was achieved in less than 24 
hours. Washing off Palbociclib allowed the cells to re-enter the cell cycle, but with variable time frames 
required for entering the S phase. To synchronize this entry, we released the cells from the CDK4 
inhibitor but at the same time, added thymidine, which is known to block the cell cycle right after entry 
into the S phase (123). We then released the cells from the thymidine block for three hours and thereby 
synchronizing the cells in the S phase (Figure 6.4 A). By doing this, we were able to disrupt the 
composition of centrosomes and analyze DNA replication without entering mitosis. Using this system 
(Figure 6.4 A), we still observed diminished DNA replication fork progression upon PLK4 inhibition in 
both Centrinone B and CFI-400945 (another potent PLK4 inhibitor) treated cells (Figure 6.4 B, E). A 
substantial decrease in the overall incorporated EdU was also observed after PLK4 inhibition in 
synchronized cells (Figure 6.4 C, D), which indicates global replicative stress captured in these cells. 
 
Furthermore, PLK4-depleted cells experienced the same effect on the fork progression (Figure 
6.4 F, G). Likewise, the depletion of centrosomal components also led to a significant reduction in the 
fork progression (Figure 6.4 H). Thus, the disruption of centrosomal composition interferes with the 




































































Figure 6.4: Impairment of centrosomes causes replication stress independent of mitosis. 
(A) Prolonged G1 arrest and synchronized entry into the S phase. H1299 cells were treated with 5 μM CDK4 inhibitor (PD 0332991, 
also known as Palbociclib) for 24, 48, or 56 hours. Cells treated with the CDK4 inhibitor for 56 hours were subsequently incubated 
with 2 mM thymidine for 16 hours. Afterward, the cells were washed and released into S phase for 3-4 hours. DNA content and 
thus, cell cycle distribution were assessed by propidium iodide (PI) staining and flow cytometry. Schematic workflow of cell 
synchronization with CDK4 inhibitor (5 μM) and thymidine (2 mM). 
(B) Cells were synchronized as outlined in (A) and incubated with 5'-chloro-2'-deoxyuridine, followed by iodo-deoxyuridine as 
indicated. Tracks of newly synthesized DNA were visualized by immunostaining of CldU (red) and IdU (green). Fork progression 
was determined through the length of the IdU label (kb/min). Two hundred fibers were measured per condition and represented 
as a boxplot. During the initial G1 arrest phase, PLK4 was inhibited throughout the experiment (including the initial G1 arrest 
phase) by Centrinone B (500 nM). 
(C) EdU incorporation of synchronized H1299 cells upon Centrinone B treatment. Cells were treated with 500 nM for 48 hours. Two 
hours before harvesting, the cells were incubated with 10 µM of EdU. The staining of the incorporated EdU was carried out using 
Click-iT, as described in the Material and Methods section. 
(D) Quantification for the global reduction in the EdU incorporation upon Centrinone B treatment. Synchronized H1299 cells from C 
were treated with 500 nM for 48 hours. Two hours before harvesting, cells were incubated with 10 µM of EdU. Staining the 
incorporated EdU was carried out using Click-iT as described in the material and methods.   
(E) Cells were analyzed as described in (B) after the treatment with 10 nM, 50 nM of CFI-400945, another potent PLK4 inhibitor. 
(F) Validation of the PLK4 siRNA efficiency using western blot as single siRNA and pooled. 10 µM of pool siRNA was used to deplete 
PLK4 in H1299 cells for 72 hours. 
(G) Analyses as in (B) but after PLK4 knockdown.  







6.5  Centrosomal disintegration induces p38/MK2 signaling, and this is required for 
replication stress  
 
Investigating a potential mechanism, which is responsible for our previous observations on 
slowing the fork progression upon centrosomes impairments, we examined the activity of p38/MK2 
signaling, a pathway that was previously shown to be necessary for reducing DNA replication by 
nucleoside analogs or CHK1 inhibition (114,124). Indeed, the phosphorylated and thus active forms 
of p38 and MK2 were strongly enhanced upon PLK4 inhibition (Figure 6.5 A), and the same was 
found for the bona fide MK2 substrate Hsp27 (125). Similar findings were reported previously, albeit 
in non-synchronized cells (126, 127). As we ruled out the possibility to have this effect due to 
chromosomal aberration, the disruption of centrosomes activates p38/MK2 signaling, independent of 
mitotic dysfunction.  
 
Next, we examined whether the activation of p38/MK2 signaling is a cause of the impaired 
DNA replication upon centrosome disintegration. We treated the cells with the PLK4 inhibitor 
Centrinone B. While assessing DNA replication using fiber assays, we incubated the cells with a 
pharmacological inhibitor of MK2 (128). And indeed, DNA replication was restored to normal levels 
by interfering with MK2 activity (Figure 6.5 B).  Corresponding to the rescue in DNA replication, we 
also expected that the cells would have a better proliferation rate and less yH2AX accumulation. To 
test this, we carried out immunostainings of yH2AX and Celigo-based experiments. As a result, both 
the level of yH2AX and cell proliferation were partially rescued by MK2 inhibition (Figure 6.5 C, D, 
and Figure 6.5 G).  Despite the observed rescue of fork progression, accumulation of yH2AX, and 
cell proliferation, MK2 inhibition did not influence centrosome number (Figure 6.5 E, F).  
 
Moreover, we performed parallel experiments upon depletion of centrosomal components and 
co-depletion of MK2 (Figure 6.5 H). Similarly, MK2 activity is highly required to interfere with the fork 
progression, accumulate yH2AX as well as inhibit cell proliferation in this context (Figure 6.5 I-K, 
Figure 6.5 N) but its activity has no impact on the centrosome number (Figure 6.5 L, M).  
 
On the contrary, overexpressing PLK4 led to enhanced fork progression even when cells were 
treated with gemcitabine through MK2 inhibition, a drug that induces replication stress (Figure 6.5 O-
Q). Thus, the observed activation of MK2 by centrosome disruption is an essential cause of the 
reduction in DNA replication fork progression, accumulation of yH2AX, and cell proliferation, but it 










































































































































Figure 6.5: Centrosomal disintegration induces replication stress through p38 and MK2. 
 
(A) Activation of the p38/MK2 pathway by PLK4 inhibition. Synchronized H1299 cells were treated with 500 nM Centrinone B for 48 
hours and analyzed by immunoblot. The phosphorylation of p38 and MK2, as well as the phosphorylation of the bona fide MK2 
substrate HSP27, each indicate activation of the p38/MK2 signaling pathway.  
(B) Synchronized H1299 cells were treated with 500 nM Centrinone B for 48 hours and 10 M MK2 inhibitor MK2iIII (termed MK2i 
from here on) for 24 hours, followed by fiber assays to quantitate DNA replication fork progression.  
(C) Accumulation of yH2AX signal in synchronized H1299 cells treated with PLK4 inhibitor with and without MK2i. Cells were treated 
with 500 nM Centrinone B for 48 hours and 10 M MK2i for 24 hours followed by immunostaining for yH2AX, and the cell nuclei 
(DAPI) (scale bar = 20 μm).   
(D) Quantification of the yH2AX signal in cell nuclei upon treatment with Centrinone B for 48 hours, followed by treatment with 10 
µM MK2i inhibitor for 24 hours. The nuclear signal was quantified using the ImageJ software. The mean and distribution of three 
biological replicates (integrated) were calculated, and the Mann-Whitney t-test assessed the significance.  
(E) MK2 activity has no impact on centrosome numbers. Synchronized H1299 cells were treated as described in B, then subjected 
to centrosome immunostaining for PCNT as a marker, and the cell nuclei (DAPI) (scale bar = 20 μm). 
(F) One hundred fifty cells were counted per each condition from E, and an average of three biological replicates are presented. 
(G) Partial rescue on cell proliferation upon PLK4 inhibition by MK2 inhibition. 5*103 H1299 cells were seeded in each well of a 24-
well plate. Cells were treated with DMSO or 300 nM Centrinone B, with or without 10 M MK2i. Confluence was measured every 
24 hours for seven days using the CeligoTM Cytometer (Nexcelom, software version 2.0). The experiment was carried out in 
three biological replicates and six technical replicates for each time point. Note that most error bars are too narrow to be 
displayed. 
(H) Rescue of the observed activation of MK2 upon centrosome depletion, using MK2 knockdown. H1299 cells were reverse 
transfected with 10 nM pooled siRNAs against CEP152 and SASS6, in combination with siRNAs to MK2, for 72 hours, followed 
by immunoblot analyses. 
(I) MK2 dependence of replication stress upon centrosome depletion. Synchronized H1299 cells were transfected as described in 
(H). Cells were subjected to fiber assays, as described in (B). 
(J) Accumulation of yH2AX signal in synchronized H1299 cells transfected with 10 nM pooled siRNAs against CEP152 and SASS6, 
in combination with siRNAs to MK2, for 72 hours followed by immunostaining for yH2AX and the cell nuclei (DAPI) (scale bar = 
20 μm).  
(K) Quantification of the yH2AX signal in cell nuclei upon depletion of centrosomal components. H1299 cells were reverse 
transfected with 10 nM pooled siRNAs, in combination with siRNAs to MK2, for 72 hours, followed by immunostaining. The 
nuclear signal was quantified using the ImageJ software. The mean and distribution of three biological replicates (integrated) 
were calculated, and the Mann-Whitney test assessed the significance.  
(L) MK2 activity has no impact on centrosomes numbers. Synchronized H1299 cells were treated as described in (H), then subjected 
to centrosome immunostaining with PCNT as a marker, and the cell nuclei (DAPI) were detected (scale bar = 20 μm).   
(M) One hundred fifty cells were counted per each condition from (E), and an average of three biological replicates are presented. 
(N) Rescue of cell proliferation upon centrosome depletion using MK2 knockdown. H1299 cells were reverse transfected with 10 nM 
of siRNA as in (H), followed by an assessment of cell proliferation as in (G) with three biological replicates and six technical 
replicates for each time point. 
(O) Increased centrosome formation upon PLK4 overexpression. Synchronized H1299 cells were subjected to plasmid transfection 
(pcDNA3, pcDNA3-PLK4) for 48 hours. Centrosomes were detected by immunostaining of PCNT, and the DAPI signal was used 
to identify the nuclei. Scale bar represents 20 μm. 
(P) PLK4 overexpression partially rescues DNA replication in gemcitabine-treated cells. Synchronized H1299 cells were subjected 
to plasmid transfection (pcDNA3, pcDNA3-PLK4) for 48 hours, followed by treatment with 300 nM gemcitabine for 2 hours before 
harvesting. DNA replication fork progression was determined using fiber assays. 
(Q) PLK4 overexpression diminishes MK2 activation in the presence of gemcitabine. Immunoblot analysis was performed to confirm 
PLK4 overexpression (note that the apparent molecular weight is increased due to the Flag tag). MK2 activity, as revealed by 






6.6  Upon centrosome disruption, the kinase MLK3 activates p38 and MK2  
 
Taking into account the crucial function of MK2 in replication stress, we sought to determine 
the upstream signaling pathway that leads to its activation in response to centrosome disruption. An 
upstream kinase of p38 that was previously found to be associated with the centrosome is MLK3 
(130), a member of the serine/threonine kinase family, and contains an SH3 domain and a leucine 
zipper-basic motif. MLK3 known with its ability to activate MAPK8/JNK kinase and functions as a 
positive regulator of the JNK signaling pathway. MLK3 is also essential for the activation of MAPK14 
(p38), MAPK3 (ERK), and MAPK8 (JNK1) through phosphorylation and activation of MAP2K4/MKK4 
and MAP2K7/MKK7. Also, it is known to have an influence on microtubule organization during the 
cell cycle. MLK3 can undergo dimerization during activation and interacts with MAP2K4/MKK4, 
MAP2K7/MKK7. It was also found in a complex with SH3RF1, RAC1, MAP2K7/MKK7, 
MAPK8IP1/JIP1, and MAPK8/JNK1 (101,115,118). Therefore, we hypothesized that the activation of 
centrosomal MLK3 is a reasonable way to activate p38/MK2 (Figure 6.6 A). 
 
Accordingly, we found that the association of MLK3 with centrosomal structures got lost in 
cells treated with the PLK4 inhibitor Centrinone B (Figure 6.6 B, C). Strikingly, MLK3 inhibition 
prevented the accumulation of phosphorylated p38 and MK2, which otherwise occurred upon PLK4 
inhibition (Figure 6.6 D), in agreement with an earlier report suggesting this possibility (130). 
Moreover, MLK3 inhibition ultimately rescued DNA replication fork progression and accumulation of 
yH2AX in the presence of the PLK4 inhibitor (Figure 6.6 E-G). Not only this, but it also seems that 
the activity of MLK3 has an impact on centrosomes number (Figure 6.6 H, I).  In the same way, MLK3 
depletion largely restored DNA replication and decreased the level of yH2AX when centrosomal 
components were knocked down (Figure 6.6 K-M). 
 
Moreover, it prevented p38/MK2 activation (Figure 6.6 J). In contrast to MK2 activation in the 
context of centrosomes number, MLK3 seems to play a crucial role in determining the centrosomes 
number under stress conditions (Figure 6.6 N, O). Thus, taking into account all of the results 
mentioned above, we conclude that similarly to MK2, MLK3 is required for a signal triggered by 
centrosome disruption to interfere with DNA replication and to maintain centrosomes number. MLK3 


































































































































































Figure 6.6: When centrosomes are disintegrated, MLK3 activates p38/MK2 to reduce fork progression.  
 
(A) Schematic diagram presenting a potential interaction between MLK3/P38/MK2.  
(B) MLK3 associates with centrosomes in a PLK4-dependent manner. Synchronized H1299 cells were treated with either DMSO or 
500 nM Centrinone B for 48 hours. Centrosomes were stained to detect PCNT and MLK3. DAPI was used to stain the nuclei 
(scale bar = 20 μm).   
(C) Quantification of MLK3 association to the centrosomal PCNT signal. Three hundred nuclei were quantified per condition. The 
results represent the quantification of two technical replicates and an average of three biological replicates. Some cells treated 
with Centrinone B did not lose the centrosome signal (PCNT), and these were the cells included in the analyses regarding the 
co-localization of centrosomes with MLK3 in our quantification. (n=3), ****P < 0.0001. 
(D) Dependence of p38/MK2 activation on MLK3. Synchronized H1299 cells were treated with 500 nM Centrinone B for 48 hours. 
During the last 24 hours, the MLK3 inhibitor URMC-099 was added at 200 nM for 24 hours, followed by immunoblot analysis. 
(E) Rescue of DNA replication by MLK3 inhibition in cells treated with PLK4 inhibitor. Synchronized cells were treated as described 
in (B) followed by DNA fiber assays, which were performed to assess replication fork progression.  
(F) Accumulation of yH2AX signal in synchronized H1299 cells treated with PLK4 inhibitor with and without MLK3i. Cells were 
treated with 500 nM Centrinone B for 48 hours and 200 nM MLK3i for 24 hours, followed by immunostaining for yH2AX, and the 
cell nuclei (DAPI) were detected (scale bar = 20 μm). 
(G) Quantification of the yH2AX signal in cell nuclei upon treatment with Centrinone B for 48 hours, followed by treatment with 200 
nM MLK3 inhibitor for 24 hours. The nuclear signal was quantified using the ImageJ software. The mean and distribution of three 
biological replicates (integrated) were calculated, and the Mann-Whitney test assessed the significance. 
(H) MLK3 activity has a partial impact on centrosomes number. Synchronized H1299 were treated as in (E). Cells were subjected 
to immunostaining with PCNT as a marker, and the cell nuclei (DAPI) was detected (scale bar = 20 μm). 
(I) Quantification of the centrosome signals per cell to DAPI-stained nuclei. One hundred fifty cells were quantified per condition 
and presented as percentage (the number of detectable centrosomes divided by the number of nuclei, multiplied by 100%) using 






(J) MLK3 knockdown diminishes p38/MK2 activation upon centrosome depletion. Synchronized H1299 cells were reverse 
transfected with 10 nM siRNAs against the targets CEP152, SASS6, and MLK3 for 72 hours. Phospho-specific antibodies were 
used to detect pathway activation. 
(K) MLK3 depletion rescued DNA replication when pooled siRNAs removed centrosomal components. Synchronized cells were 
treated as in (J) and then subjected to DNA fiber assays. 
(L) Accumulation of yH2AX signal in synchronized H1299 cells treated as in (J), followed by immunostaining against yH2AX and 
the cell nuclei (DAPI) (scale bar = 20 μm). 
(M) Quantification of the yH2AX signal in cell nuclei upon centrosomal components depletion for 72 hours with and without MLK3 
knockdown. The nuclear signal was quantified using the ImageJ software. The mean and distribution of three biological replicates 
(integrated) were calculated, and the significance was assessed by the Mann-Whitney test. 
(N) MLK3 activity has a partial impact on centrosomes numbers after knocking down CEP152 but not after knocking SASS6. 
Synchronized H1299 cells were treated as in (J), then subjected to centrosome immunostaining with PCNT and DAPI (scale bar 
= 20 μm).  
(O) Quantification of the centrosome signals per cell to DAPI-stained nuclei. Synchronized H1299 cells treated as in (N). One 
hundred fifty cells were quantified per condition and presented as percentage (the number of detectable centrosomes divided 




6.7  Centrosome disintegration induces the formation of RNA: DNA hybrids that are 
required for replication stress 
 
Replication stress is often driven by unscheduled transcription and the formation of R-loops, 
i. e. RNA hybridizing to DNA (often in association with transcription) and displacing the opposite DNA 
strand (60) (Figure 6.7 A). Accordingly, upon PLK4 inhibition, we detected the formation of RNA: 
DNA hybrids using immunostaining with the monoclonal antibody S9.6 directed against these 
structures (Figure 6.6 B, C). Upon staining fixed cells in situ, the immunofluorescence signal derived 
from antibody binding was prominent in discrete nuclear structures, compatible with the concept that 
R-loops mainly occur at specific sites of highly active transcription (131-134). In contrast, the 
overexpression of RNaseH1, an RNase that cleaves the RNA component of RNA DNA hybrids, 
sharply reduced the nuclear immunostaining signal, confirming the specificity of the antibody (Figure 
6.7 B, C). Similarly, in the dot blot analyses, the accumulation of R-loops was also observed upon 
PLK4 inhibition as well as centrosomes depletion (Figure 6.7 D-G), and RNAseH1 treatment sharply 
reduced the signal (Figure 6.7 D, E), confirming that RNA: DNA hybrids are the source of the antibody 
signal. Interestingly, the inhibition of p38/MK2 signaling also diminished the formation of R-loops 
upon centrosomal impairment, consistent with the rescue of DNA replication by the same inhibitors 
(Figure 6.7 H-K). 
 
To clarify the causal link between R-loop formation and replication stress, we performed DNA 
fiber assays. Upon PLK4 inhibition, the progression of the DNA replication forks was largely rescued 




















































































































Figure 6.7: Replication stress upon centrosome disintegration requires RNA:DNA hybrids. 
(A) The schematic diagram explains some factors leading to unscheduled replication–transcription conflicts.  
(B) Immunostaining of the R-loop signal in cell nuclei upon treatment with Centrinone B and/or synchronized H1299 cells transfected 










hours, along with 500 nM Centrinone B treatment. The nuclei (DAPI) and RNA: DNA hybrids (antibody S9.6) were detected 
(scale bar = 20 μm). 
(C) Quantification of the R-loop signal in cell nuclei upon treatment with Centrinone B and/or transfection with an expression plasmid 
for RNaseH1. The nuclear signal was quantified using the ImageJ software. The mean and distribution of three biological 
replicates (integrated) were calculated, and the significance was assessed by the Mann-Whitney test. 
(D) Dot-blot analysis of RNA: DNA hybrids in synchronized H1299 cells. Cells were treated either with DMSO, 500 nM Centrinone 
B, or 10 nM CFI-400945 for 48 hours. Genomic DNA from the cells was spotted onto a nitrocellulose membrane with or without 
prior treatment with RNaseH1. The dots were stained with an S9.6 antibody to detect RNA: DNA hybrids. For normalization, an 
antibody against single-stranded DNA (ssDNA) was used to stain an additional set of dots that had been treated with acid for 
denaturation. 
(E) Quantification of the S9.6 signal on the membrane from (D). The signal obtained with S9.6 was normalized to the ssDNA signal 
first and then to the control treatment. Each column represents the average of three biological replicates with three technical 
replicates each. 
(F) Dot-blot analysis of RNA: DNA hybrids in synchronized H1299 cells. Cells were reverse transfected with pooled siRNA for 72 
hours, followed by Dot-blot analysis as described in (D).  
(G) Quantification of the S9.6 signal on the membrane as described in (E). The signal obtained with the S9.6 antibody was 
normalized to the ssDNA signal first and then to the control treatment. Each column represents the average of three biological 
replicates with three technical replicates each. 
(H) Immunostaining of the R-loop signal in cell nuclei upon treatment with Centrinone B for 48 hours and 10 µM MK2i for 24 hours. 
The nuclear signal was visualized by staining the cells with S9.6 antibody and 4′, 6-Diamidin-2-phenylindol (DAPI) was used to 
delineate the nuclei (scale bar = 20 μm). 
(I) Quantification of the R-loop signal in cell nuclei upon treatment with Centrinone B for 48 hours, followed by treating the cells with 
10 µM MK2iIII for 24 hours. The nuclear signal was quantified using the ImageJ software. The mean and distribution of three 
biological replicates (integrated) were calculated, and the significance was assessed using the Mann-Whitney test. 
(J) Representative dot blot showing the rescuing of accumulation of RNA: DNA hybrids upon MLK3/MK2 inhibition. 
(K) Quantification of the S9.6 signal on the membrane corresponding to dot blot in (J). The signal obtained with S9.6 was normalized 
to the ssDNA signal first and then to the control treatment. Each column represents the average of three biological replicates 
with three technical replicates each. 
(L) Validation for RNAseH1 overexpression in synchronized H1299 cells.  
(M) The resolution of RNA: DNA hybrids by RNAseH1 rescues DNA replication fork progression upon Centrinone B treatment. Cells 




















6.8  PLK4 inhibition leads to activation of the transcription factors ATF2 and JUN, 
downstream of the p38/MK2 pathway 
 
During the process of DNA synthesis and in every entry into S-phase, the DNA replication 
machinery is threatened by multiple intrinsic factors that can lead to DNA damage and genomic 
instability, such as lesions that interfere with fork progression, tightly associated DNA-protein 
complexes, and transcription-replication conflicts (65). Therefore, cells must overcome these 
obstacles to ensure faithful DNA replication and chromosome duplication. However, if the cell fails to 
overcome these barriers, this will eventually lead to genomic instability and reduced cell viability, a 
hallmark of cancer, and aging. Both DNA replication and transcription are vital cellular processes. 
Both types of machinery are competing over the same DNA template, which increases the chance of 
the two types of mechanisms colliding with each other under certain circumstances. 
 
For the reasons mentioned above, we next searched for a mechanism that may drive 
unscheduled transcription and lead to the formation of RNA: DNA hybrids. To investigate whether 
global transcription is indeed responsible for compromised DNA replication, we used an inhibitor of 
Cdk9 to shut down transcription, as described previously (78,104), exploring potential transcription 
factors downstream of p38/MK2 signaling that may play a role in our scenario. Upon activation of p38 
and MK2, the transcription factors ATF2 and JUN (also known as c-Jun) are phosphorylated and 
form a dimer to stimulate transcription (82,103,130). ATF2 is a member of the leucine zipper family 
of DNA binding proteins and is known for its ability to form a homodimer or a heterodimer with c-Jun, 
which further stimulates transcription (32-34). 
 
Accordingly, we detected an increase in the phosphorylation levels of ATF2 and JUN upon 
Centrinone B treatment (Figure 6.8 A). In this context, ATF2/JUN phosphorylation was dependent on 
MK2 and MLK3 (Figure 6.8 C). At the same time, we observed the accumulation of both transcription 
factors in the chromatin fraction (Figure 6.8 B).  While CDK9 inhibition rescued DNA replication in the 
presence of the PLK4 inhibitor Centrinone B (Figure 6.8 F), JUN depletion also restored DNA 
replication when PLK4 was inhibited (Figure 6.8 D, E). Since JUN-mediated transcription affects a 
multitude of genes, possibly leading to unscheduled RNA accumulation, we hypothesized that JUN 
activation might contribute to the observed replication stress but not only.  
 
To clarify the relationship between the activation of ATF2/JUN and replication stress, we 
performed DNA fiber assays after depleting JUN and treating the cells with Centrinone B. To test 
whether JUN is the main reason for transcription activation, we carried out dot blot analysis. This 





inhibitor rescues it completely, indicating that JUN is part of this activation but not the only one (Figure 
6.8 G, H). We conclude that interfering with centrosome integrity leads to replication stress partially 



































































Figure 6.8: PLK4 inhibition activates ATF2 and JUN to induce replication stress. 
(A) Phosphorylation of ATF2 and JUN after Centrinone B treatment (500 nM, 48 hours) revealed by immunoblot analysis. Note the 
additional accumulation of TBP, the reduction in the repressive Histone 3 trimethylation at K27, and the increase in H3K27 









(B) JUN and ATF2 associate with the chromatin fraction upon Centrinone B treatment. Chromatin fractions were isolated and 
compared to the cytoplasmic supernatant. MCM7 (chromatin) and GAPDH (cytoplasm) were used to control the fractionation. 
The gel is a representative example of 3 biological replicates.  
(C) ATF2/JUN phosphorylation is dependent on the activity of MLK3 and MK2. H1299 cells were treated as described in (A) in 
addition to MLK3i, MK2iIII, and MEKi (U0126). The phosphorylation levels of ATF2 and JUN were assessed using immunoblot 
analysis. 
(D) Western blot analysis showing the validation of JUN knocked down after 72 hours. 
(E) The impairment of DNA fork progression upon Centrinone B treatment is dependent on JUN. Synchronized H1299 cells were 
reverse transfected to knock down JUN and treated with 500 nM Centrinone B for 48 hours. DNA fiber assays determined fork 
progression. 
(F) Blocking the global transcription machinery using a Cdk9 inhibitor rescues DNA fork progression upon PLK4 inhibition. 
Synchronized H1299 cells were treated with either DMSO or 500 nM Centrinone B for 48 hours, and 2 hours before harvesting, 
the cells were treated with 10 µM Cdk9 inhibitor. DNA fiber assays were performed to assess fork progression. 
(G) Dot blot analysis of synchronized H1299 cells treated as indicated underneath the figure. Genomic DNA from the cells was 
spotted onto a nitrocellulose membrane with or without prior treatment with RNaseH1. The dots were stained with the S9.6 
antibody to detect RNA: DNA hybrids. For normalization, an antibody against single-stranded DNA (ssDNA) was used to stain 
an additional set of dots that had been treated with acid for denaturation. 
(H) Quantification of the S9.6 signal from Dot blot in (G). The signal obtained with S9.6 was normalized to the ssDNA signal first and 




6.9   MK2 inhibition rescues defects in replication and proliferation of cells from 
patients with Seckel syndrome  
 
Seckel syndrome an autosomal recessive disorder displayed by growth retardation, 
microcephaly, minimal head, intellectual disability, and unique facial features, such as large eyes, 
beak-like nose, and narrow face. Seckel syndrome can be caused by mutations in several 
centrosomal components, carry out by nine components such as have been described (32, 51). The 
initial suspicion that centrosomes might govern DNA replication had come from the fact that genetic 
defects of centrosomes on the one hand and the replication stress kinase ATR, on the other hand, 
each lead to highly overlapping phenotypes in Seckel syndrome (32,112). Therefore, we asked 
whether the cells from patients suffering from a centrosomal defect causing Seckel syndrome might 
also display the features of replication stress. Indeed, human fibroblasts from a patient with Seckel 
syndrome with a defect in the centrosomal component CEP152 (32)  showed a substantially slower 
replication fork progression than fibroblasts from healthy donors (Figure 6.9 A). 
 
Moreover, the Seckel cells had increased MK2 activity, as determined by the phosphorylation 
of the corresponding signaling intermediate (Figure 6.9 B). Strikingly, MK2 inhibition rescued the 
progression of replication forks in Seckel cells despite the accumulation of P53, which can be due to 





mediate the phosphorylation of p53 at Ser20 (135) and may thus alter its activity even when its levels 
are unchanged. Moreover, although Seckel fibroblasts grew substantially more slowly than normal 
fibroblasts, incubation with MK2 inhibitor led to equally efficient growth of all cells alike (Figure 6.9 
D). Thus, centrosome disintegration in patients with Seckel syndrome leads to MK2 activation and 
replication stress as a consequence. The fact that MK2 inhibition restores DNA replication and 


























Figure 6.9: MK2 inhibition facilitates DNA replication and proliferation of cells derived from a patient with Seckel syndrome. 
(A) The MK2 inhibitor MK2i III rescues DNA replication fork progression in cells from a Seckel patient carrying a deletion in the 
CEP152 gene. Human breast fibroblasts (control-1), human skin fibroblasts (control-2), and skin fibroblasts from a Seckel patient 
(CEP152 mutant) were treated with 20 µM MK2iIII for 48 hours, followed by fiber assays. 
(B) The MLK3-p38-MK2 pathway was constitutively activated in Seckel syndrome cells. Control-1, control-2, and Seckel cells 
(deletion in CEP152) were harvested after 48 hours of 20 µM MK2i III treatment and subjected to immunoblot analysis. 







(D) The restored proliferation rate of Seckel cells upon MK2 inhibition. 5*103 control-1, control-2, and Seckel cells were seeded in 
wells of a 24-well plate and treated with either DMSO or 10 M MK2i III. A Celigo Cytometer was used to determine cell 









In this thesis, we demonstrate a direct connection between DNA replication and 
centrosome integrity during S phase. Strikingly, centrosome disruption leads to an impairment of 
DNA replication even when cells are not allowed to undergo mitosis. Centrosomes support DNA 
replication by regulating the MLK3-p38-MK2 signalling pathway as well as suppressing the 
formation of RNA:DNA hybrids (R-loops). Based on that, this thesis determines a mechanistic link 
between the duplications of two major elements, which need to be duplicated once and only once 
every cell cycle - the genome and the centrosomes. 
 
7.1  The depletion of centrosomal components reduces DNA replication fork 
progression in H1299 cells 
 
       Centrosomes serve as the microtubule-organizing centers and contribute to cell division. 
They consist of two centrioles, each one is being surrounded by multiple proteins (6, 8). These 
proteins are responsible for various functions, such as centrosome duplication, microtubule 
nucleation, and elongation. Centrosome abnormalities have been observed in several cancer 
types. Defects, such as centrosome amplification, are associated with poor prognosis, metastasis, 
aggressiveness, and drug resistance (6, 8). Therefore, for the last few years, there has been an 
increasing interest in studying centrosomes, especially in cancer. Understanding the biology 
behind centrosomal abnormalities can help us to find a suitable way to target these organelles to 
achieve a better survival outcome. Investigating how centrosome abnormalities promote 
tumorigenesis is not a new field of research. A century ago, Theodor Boveri proposed that 
increased centrosome numbers are a pro-tumorigenic driver. Years after Boveri’s hypothesis, 
cancer biologists included centrosome amplification to the hallmarks of cancer (3).  
 
      Centrosome duplication is a crucial step in centrosome biogenesis, much like DNA 
replication, and it is tightly regulated to ensure the one-time duplication every cell cycle. The 
process of centrosome duplication at G1 phase starts with the recruitment of both CDK2 and 
PLK4 to centrosomes to initiate the duplication process. The recruitment process of CDK2 and 
PLK4 is carried out by the scaffold proteins CEP152 and CEP192 (10, 11). The loss of CEP152 






duplication and, therefore, failure in centriole duplication and loss of centrioles. In addition to that, 
loss of CEP152 contributes to further delay in the recruitment of SAS6 to centrosomes, impairing 
centrosome duplication, and driving the formation of monopolar mitotic spindles during mitosis 
(10, 11). Similar to what is known in the filed of centrosomes biogenesis, in our experiments, we 
observed a significant reduction in the detectable centrosomes (Pericentrin) upon  CEP152, 
CEP192 knock down, as well as SASS6 and CCP110 knock down(Figure 6.1).  
 
      CEP192 is another centrosomal component that we investigated in our study. It is 
essential for the recruitment of pericentriolar material (PCM) and plays a role in centrosome 
maturation and duplication (11). Finally, CCP110 is an additional centrosomal protein required for 
centrosome duplication but at a different stage of pro-centriole formation. CCP110 caps the distal 
tips of pre-existing centrioles, and by doing this, along with CEP97, it controls the length of pro-
centrioles by polymerization and de-polymerization of y-tubulin (16). CCP110 is also required for 
correct spindle formation, regulation of cytokinesis, and, therefore, genomic stability (137). 
Previously, it has been shown  that depletion of different centrosomal components could lead to 
different alterations of centrosomes. For example, the group of Chen found that loss of CCP110 
results in premature centrosome separation, and abolishes centrosome reduplication in S-phase-
arrested cells (137). 
 
       As previously stated by Le Clech et al. 2009 (16), depleting SASS6 weaken centrosome 
duplication by impairing the growth of the procentriole (138). In agreement with previous 
knowledge, we also observed a defect in centriole duplication in all of the cases. We also tried to 
detect any significant differences in the morphology of the centrosomes, but detecting such 
differences might require higher resolution than the one available by standard microscopy. In 
addition to the reduction of centrosomes, we also observed the induction of replication stress 
when depleting these components. Thereby, we can conclude that the various phenotypes 
induced by the knockdowns overlap but are distinct. Yet what they all have in common is the 
defects in the duplication of centrioles and the induction of replicative stress.  
 
      Targeting centrosomes might represent a plausible way to treat cancers that exhibit 
centrosome amplification. As PLK4 is one of the leading players in centrosome duplication, and 
it is not only responsible for the initiation of duplication but also responsible for maintaining the 
correct centrosome number within the cell, therefore developing drugs to target PLK4 would be 






triggered by the recruitment of PLK4 to the centrosomal site leading to the interaction between 
the recruited PLK4 and STIL. the interaction between PLK4-STIL induces the auto-
phosphorylation of PLK4 to activate STIL. The phosphorylation of STIL by PLK4 triggers the 
recruitment of SAS-6 and cartwheel assembly to ensure the 9-fold symmetry (1, 2, and 8). While 
the inhibition of PLK4 leads to aberrant centriole duplication during the early stages of the cell 
cycle G1/S phases (14,15), the overexpression of PLK4 leads to centrosome amplification 
through the simultaneous generation of multiple pro-centrioles adjoining to each parental centriole 
during the S phase (83). PLK4 is not only required during the early stages of the cycle (G1/S 
phase), but it seems like it is also needed during the later stages to maintain the integrity of 
centriolar satellites, as previously reported (140,141). PLK4 is also required for the 
phosphorylation of CDC25C and CHK2, which regulate the entry into mitosis (30, 83). Consistent 
with the important role of PLK4 in controlling centriole duplication, its activity as well as its level 
need to be tightly regulated. For this reason, PLK4 represents a possible target for cancer therapy. 
Since 2013 several PLK4 inhibitors have been developed to serve this purpose, one of which 
sucessed to enter the clinical trial; the PLK4 inhibitor CFI-400945. CFI-400945 showed high 
efficacy in animal models of breast and ovarian cancers. It was further tested in patients with 
advanced tumors in phase I clinical trials and is currently being tested in phase II clinical trials in 
patients with advanced/metastatic breast cancer (ClinicalTrials.gov Identifier: NCT03624543, 
2018). Pre-clinical trials with CFI-400945 have shown that inhibiting PLK4 causes aberrant 
chromosome numbers, which in turn leads to mitotic catastrophe and cell death (81, 82). PLK4 
inhibition using CFI-400945 shrinks the size of the tumor in animals and exhibits anti-tumor activity 
in patients with low side effects (82). 
 
     Despite the impressive outcomes of CFI-400945, it is essential to keep in mind that this 
small compound promotes mitotic catastrophe and cell death through centrosome amplification 
(81). Whether the observed effect is due to targeting PLK4 or Aurora kinases or both is still 
unclear. Since centrosome amplification drives tumorigenesis, some legitimate concerns need to 
be addressed regarding the CFI-400945 inhibitor. For example, what would happen to the cells, 
which manage to evade the mitotic catastrophe caused by CFI-400945? Do these cells become 
more resistant to other treatments, thus becoming more aggressive? To answer these questions, 
further studies should be carried out on CFI-400945. 
 
      In 2015, (108) another PLK4 inhibitor called Centrinone B was described. Centrinone B is 






vertebrate cell types. Similar to what was previously described (108), the inhibition of PLK4 by 
Centrinone B reduces the total number of centrosomes in H1299 and other cell lines. Additionally, 
we also showed that the status of p53 had no significat impact on centrosome number nor DNA 
fork progression upon PLK4 inhibition, suggesting that PLK4 is highly required for centrosome 
duplication in different cancer types .  
 
      In dividing cells, centrosome integrity can influence the rate of cell division (81, 82,108).  
We observed that inhibition of PLK4 reduced cellular growth, but not only, it also managed to 
induce DNA replication stress in several human cancer cell lines. While the observed effect 
appears to be a direct effect of Centrinone B on PLK4, the exogenous overexpression of PLK4 in 
H1299 rescued the DNA replication fork progression and increased resistance towards 
gemcitabine (Figure 6.3), suggesting a potent pro-proliferative function of PLK4.  
 
      In summary, the increase in PLK4 expression was found in medulloblastoma, breast, 
colorectal, prostate, and ovarian cancers (83), which motivated many scientists to investigate 
PLK4 as a target for cancer therapy. Even though only one PLK4 inhibitor managed to make it to 
clinical trial phase II, this had opened the way to the development of similar centrosomal inhibitors. 
Moreover, it might be worthwhile to test other centrosomal biomarkers, which can be used as a 
target for cancer therapy in addition to PLK4 (13). In vitro studies indeed showed that 
overexpression of SAS6 (12), STIL (13) and pericentrin (13) could also lead to centrosome over-
duplication, but this needs to be further explored.  
 
7.2  PLK4 inhibition drives cells towards polyploidy   
      Aneuploidy, or imbalanced chromosome number, has been studied for decades and was 
proven to be a mechanism that profoundly affects cell functions. Moreover, aneuploidy is very 
frequent in cancer, and it is often associated with a more complex phenotype called chromosomal 
instability (CIN). It is also known that chromosomal instability and aneuploidy in cancer correlate 
with resistance to drugs, metastasis, and disease progression (107). 
 
      Several mechanisms can lead to aneuploidy: firstly, chromosome segregation errors, 
which result from incorrect attachments of the spindle microtubules to the kinetochore; secondly, 
oncogenic activation and/or tumor suppressor inactivation; thirdly, the fidelity of chromosome 






of Rb-E2F and Ras activation (107). Accordingly, the gain of a single extra chromosome can 
strongly affect cell proliferation.  
 
      Centrosome abnormalities known to be correlated with chromosomal instability (CIN), 
such as; insufficient levels of PLK4 known to be associated with abnormal spindle poles (4). 
However, it is still unknown to what extent CIN results from a direct impact on the spindle and, 
most importantly, to what extent DNA replication stress is involved. What would also be interesting 
to address is what comes first, CIN or DNA replicative stress, thus, is CIN driving DNA replicative 
stress or vice versa?   
 
      Chromosomal instability (CIN) is known to be a source of replicative stress (113). 
Therefore, in continuously cycling cells, we cannot rule out the possibility that the observed 
reduction in fork progression could be a result of chromosomal missegregation rather than a direct 
effect on the DNA replication machinery, especially when all of our treatment timelines are 
between 48 and 72 hours. Therefore, we tested when and to what extent centrosomal depletion 
through PLK4 inhibition can induce aneuploidy using chromosomal spreading and FACS analysis. 
 
      We have shown that the PLK4 inhibitor Centrinone B reduces cell proliferation and  
centrosome number, which is in agreement with what was previously described (108). 
Additionally, we also showed that PLK4 inhibition impaired the progression of the replication fork. 
Using both chromosomal spreading and FACS analysis, we observed an increase in polyploidy 
upon Centrinone B treatment only after seven days of treatment. Thus, we can safely argue that 
the reduction in fork progression is not a result of aneuploidy but rather a result of constant 
interfering with the DNA replication machinery.  
 
7.3  Centrosome integrity is essential to avoid DNA replication stress even 
independently of mitosis 
 
      Centrosomes function as the microtubule-organizing center in interphase and mitotic cells. 
In addition, they might also play a role in the regulation of cell cycle progression itself, since laser 
ablation or surgical removal of centrioles lead to failure in cytokinesis and G1 arrest, despite the 
observed slower cell cycle progression (84). Similarly, we have also shown that cells with knocked 
down centrosome components or inhibited PLK4 also experienced a slower cell division (Figure 






centrosome duplication and DNA replication. Multiple evidence could support this coordination, 
such as the activation and inactivation of the serine/threonine cyclin-dependent protein kinases 
(CDKs) (85), e.g., CDK1 and cyclin B. CDK2 activation is required not only for rapid DNA 
replication (87), but it has also been shown to be essential for the activity of centrosomes during 
the G2/M transition, as demonstrated by Bailly et al. (86), and later on the importance of CDK2 in 
controlling centrosomes duplication was also revealed(84) . Moreover, CDK2 activity is a crucial 
regulator of the centrosome cycle, such as centrosomes duplication (11, 12, and 26) and 
separation of the centriole pair (13, 80). However, the signaling pathways involved in controlling 
the initial activation of CDK1/2 at the centrosome remain enigmatic.  
 
      Both centrosome duplication and DNA replication are controlled by the retinoblastoma 
tumor suppressor pathway, a pathway that governs the expression of the transcription factor E2F, 
which is responsible for S phase progression (142,143). Inhibiting DNA replication using 
hydroxyurea (HU) led to centrosome amplification in pRb deficient human and mouse fibroblasts 
(144), but also interfering with centrosomes causes replication stress throughmalfunctioning of 
the mitotic spindle (89), indicating that the centrosome cycle could be partially dependent on DNA 
replication (88, 144). When centrosomes disintegrate, mitotic fidelity can be decreased, thus 
enhancing the missegregation of sister chromatids, leading to numerical chromosomal instability 
(CIN), which would then result in replication stress, as recently observed in cells with 
supernumerary chromosomes (113). Therefore, in continuously cycling cells, we cannot rule out 
such a scenario even though we could not observe aneuploidy before the seventh day of 
treatment, yet having lagging or broken chromosomes is known to be sufficient to induce 
replicative stress.   
 
      Our previous results using chromosomal spreading analysis indicate that Centrinone B 
induces aneuploidy after seven days of treatment. Therefore, we aimed to prevent the cells from 
entering the cell cycle under treatment to further avoid the consequences which may arise from 
the M phase in dividing cells. Moreover, as one of our main aims in this study, we sought to 
investigate whether the impairment of centrosome components has a direct impact on the DNA 
replication machinery independently from chromosome missegregation (89). 
 
      To address this question, we arrested the cells in G1 phase for 48 hours using a CDK4/6 
inhibitor during siRNA transfection or PLK4 inhibitor treatment (Figure 6.4). Using this system, we 






Interestingly, centrosome disruption always leads to replication stress even without any passage 
through mitosis (Figure 6.4), which remained true across all treatments. Our results indicate that 
centrosomes might not be strictly required for mitotic spindle assembly but instead have other 
functions, such as maintaining the processivity of DNA replication independently of mitosis and 
apart from polyploidy. The role of centrosomes in mitosis is a topic that is still under debate. It has 
become evident that centrosomes are not strictly required for mitotic division in all cell types, but 
instead, they contribute to the accuracy of mitosis in some cell types (7). It is thus very intriguing 
to hypothesize that the role of centrosomes in DNA replication might be at least as necessary as 
their contribution to the accuracy of mitotic cell division. 
 
7.4  Depletion of centrosomal components triggers the p38/MK2 signaling 
pathway, leading to replication stress  
 
      Several checkpoints control the G1/S and G2/M transitions to ensure a faithful cell division 
(90). They are also associated with centrosomes and/or appear to play an essential role in 
centrosome homeostasis (91, 92). For instance, the tumor suppressor p53 controls both G1/S 
and G2/M checkpoints, and its inactivation leads to dysregulation of the centrosome cycle (93). 
In human cancers, mutations in p53 correlate with the occurrence of centrosome amplification in 
carcinomas of the breast, head and neck, prostate, and in neuroectodermal tumors (94). In 
cultured cells, tumors derived from p53-null and p53 wild-type mice, which are associated with 
cyclin E overexpression synergistically, increased the frequency of centrosome amplification (95).  
These previous findings suggest that an imbalance between negative and positive cell cycle 
regulators could accelerate centrosome defects. 
 
      In this project, we aimed to search for a plausible mechanism that might impair DNA 
replication fork progression upon centrosome disintegration. We have previously characterized 
the role of MK2 in replication stress. In response to irradiation, treatment with gemcitabine, or 
CHK1 inhibition, the resulting replication stress highly depends on MK2 activity. At least in part, 
the rescue of fork progression after MK2 inhibition/depletion was a result of the reactivation of 
translesion synthesis polymerases, and accordingly, DNA polymerase eta was shown to be a 








      Indeed, the phosphorylated and thus, the active forms of p38 and MK2 were strongly 
enhanced by PLK4 inhibition (Figure 6.5), and the same was found for the bona fide MK2 
substrate HSP27. Thus, disruption of centrosomes activates p38/MK2 signaling independently of 
mitotic insults. The available pieces of literature show that p38 can be triggered by centrosomes 
impairment, followed by activation of p53-p21-dependent G1-S arrest and that the activation of 
p38 is vital for this activation (126).  Moreover, the Suhail et al. reported that the depletion of 
TACC3, a critical centrosomal protein that is up-regulated in many cancers, lead to G1 arrest and 
cell death through activation of the p38-p53-p21 stress signaling pathway (145).  Similarly, we 
found that depleting other centrosomal components, such as PLK4, CEP152, and SAS6, also 
lead to the activation of p38/MK2 pathway and impairment of the replication fork. Altogether, we 
suggest that this signaling pathway is triggered by centrosome disruption, resulting in diminished 
progression of DNA synthesis.  
 
7.5  MLK3 acts as the first sensor towards impairment of centrosomes, followed 
by activation of the p38/MK2 pathway  
 
      Several studies showed that multiple proteins could influence both mechanisms - 
centrosome duplication (79,126) and DNA replication (39, 40, and 41). The Cyclin E/Cdk2 
complex is known to regulate both DNA replication and centrosome duplication during the G1/S 
phase of the cell cycle (98). It was also shown that the initiation of DNA replication requires the 
placement of Cyclin E/Cdk2 to the centrosomes site by a domain of 20 amino acids known as 
centrosomal localization sequence (CLS) (98).  
 
      CHK1 kinase was also suggested to be associated with centrosomes in interphase rather 
than in the mitotic phase. CHK1 negatively regulates entry into mitosis by inhibiting the activation 
of cyclin B/CDK1 under abnormal cell conditions. The kinase works as a shield towards 
centrosomal CDK1 by protecting it from unscheduled activation, thereby contributing to the proper 
timing of the initial steps of cell division, including mitotic spindle formation (99).      
 
      Searching for potential candidates which can explain the activation of P38/MK2 upon 
centrosomes impairment and in response to that inducing replicative stress, we investigated the 
mixed-lineage kinases 3 (MLK3). MLK3 is a MAP3K11 kinase known for its ability to activate 
MKK3/6 /c-JUN/JNK/ERK (100,115) as well as for its association with centrosomes (116).  It has 






MAPK3K BRAF, by bridging them together, leading to the activation of RAF-1 (117, 118). 
Moreover, MLK3 activation was mostly enhanced during G2/M to regulate the microtubule 
organization during mitosis in transformed HeLa cells, while inhibiting MLK3 using CEP-11004 
managed to block mitotic progression and caused cells to arrest in pro-metaphase (146). 
Furthermore, MLK3 expression has also been reported to promote activation of the MAPK p38 
pathway, NF-κB (100), and p70 S6 kinase (101). On the other hand, depleting this kinase was 
neither toxic to cells, nor essential for progression through the cell cycle, but its activity was 
required to increase the sensitivity towards taxol compounds (147).  
 
      We tested whether centrosomal MLK3 could play a role in the regulation between DNA 
replication and centrosome duplication, independently of mitosis. In agreement with all previous 
findings, we observed MLK3 co-localization to the site of centrosomes during S phase. We also 
found a high dependency on MLK3 to activate p38/MK2, suggesting a close regulatory 
association of the three kinases. One function of this complex is the transmission of a signal that 
connects the replication of centrosomes and the cellular DNA. It was also known that MLK3 could 
localize to centrosomes, and it appears to regulate microtubule organization during mitosis in a 
JNK-independent fashion (146). MLK3 can interact with several scaffold proteins known as JNK 
interacting proteins (JIPs), JIP1, JIP2, and JIP3 to relocate themselves inside the cell. In addition 
to that, JIPs are recognized as the cargos for the molecular motor kinesin, the motor protein that 
moves along microtubule filaments. The association of MLK3 with JIP may provide further 
explanation of the dynamic cellular distribution of MLK3 (100, 101). 
 
      Our results indicate that there might be an increased cancer risk associated with targeting 
MLK3 since centrosome malfunction would no longer be sensed through MLK3 activation and 
replication stress. This possibility should be evaluated in animal cancer models before taking the 
approach to patients. In summary, we suggest that the initial steps of an accurate DNA replication 
require highly intact centrosomes at the G1/S transition and that MLK3 works as a guardian of 










7.6  Centrosome disintegration induces RNA:DNA hybrids, an additional source 
of DNA replication stress, in part through the activation of the transcription factor 
ATF2/JUN downstream of p38/MK2 
      Based on the activation of p38/MK2 via centrosomal MLK3 activity upon centrosome 
impairment and the potential involvement of the JUN/ERK pathway (149), a pathway known to 
strongly activate several transcription genes (149), we,  decided to test whether the transcriptional 
machinery was activated due to centrosomes impairment. It is known that upon activation of p38, 
several transcription factors are being activated, such as ATF2, which is a transcription factor 
activated by several stress kinases including JNK (MAPK8, MAPK9, MAPK10) and p38 (MAPK1, 
MAPK11, MAPK12, MAPK13, MAPK14) (148). It was perviously shown that ATF2 can affect the 
transcriptional regulation of early genes regulating stress responses and DNA damage responses 
(102,148). Upon activation of ATF2 by different stress stimuli, ATF2 forms homodimers or a 
heterodimer with JUN (103), inducing the translocation of the complex to the nucleus. ATF2 is 
known to be phosphorylated on threonine 69 and/or 71 by JNK or by p38 in response to stimuli 
or by ATM on serines 490 and 498 (150). On the one hand, the phosphorylation on Thr69 and 
Thr71 of ATF2 and its dimerization are required to induce its transcription factor activity, which 
further activates the transcriptional activator protein 1 (AP-1).  The phosphorylation on serines 
490 and 498 revealed another role for ATF2 as a participant in the DNA damage response (151). 
We confirmed the activation of the transcription machinery by screening for transcriptional 
markers, such as H3K27ac and H3K27me3, and we also observed the activation of ATF2 and 
JUN (Figure 6.7). In addition, we showed the translocation of these transcription factors 
ATF2/JUN to the nucleus, as well as their dependency on active MLK3. Considering all these 
findings, in which centrosomes impairment present an additional way to activate transcription 
machinery, we sought to test whether the observed imbalance in transcription levels could lead 
to a conflict with the DNA replication machinery through the generation of R-loops. 
 
      Conflicts between transcription and DNA replication represent a significant cause of 
replication stress (104). Several mechanisms have been suggested for R-loops forming obstacles 
to the DNA replication machinery (60,104). Such conflicts may not merely result from collisions 
between RNA- and DNA-polymerases, but rather from the co-transcriptional occurrence of 
RNA:DNA hybrids with an additional single DNA strand, the so-called R-loop. It was shown that 
R-loops hinder DNA replication forks from progressing (60), leading to the assumption that R-






explanation for the observed reduction in fork progression through the activation of transcription 
machinery upon impairment of centrosomes. 
 
      Thus, we tested whether R-loop formation generated due to the activation of transcription 
factors might be implicated upon centrosomes impairment. Notably, our results strongly suggest 
that depletion of PLK4 induces R-loops and therefore interferes with DNA replication (Figure 6.6), 
whereas DNA replication could be restored by RNase-mediated removal of R-loops. Moreover, 
the observed accumulation of R-loops was dependent on the activity of MLK3/MK2. 
 
      RNA metabolism is becoming a significant focus in current research on DNA replication 
stress. RNA processing factors constitute a substantial fraction of kinase substrates upon DNA 
damage (105), making it plausible that such factors might affect DNA integrity, perhaps through 
R-loop formation. Therefore, targeting centrosomal components in cancer cells is expected to 
have a more profound impact on cancer cell proliferation by interfering with DNA replication 
through transcription-replication conflicts. The raised conflict by itself encourages the continuous 
evaluation of PLK4 as a drug target. 
 
 
7.7  MK2 inhibition rescues defects in DNA replication and proliferation of 
Seckel syndrome patient cells    
      Seckel syndrome is a genetically heterogeneous disorder that can be caused by a 
mutation in mainly ten genes, including ATR, RBBP8, CEP152, CENPJ, PLK4, CEP63, DNA2, 
ATRIP, NIN and CDK5RAP2 (109). The syndrome is characterized by growth retardation, 
microcephaly, reduced head circumference, intellectual disability, and unique facial features, such 
as large eyes, beak-like nose, and narrow face. This phenotype resembling human Seckel 
syndrome, including primary microcephaly, was also found in mice with a targeted deletion of 
CEP63 (52). Classically, both the human Seckel syndrome and its murine model were described 
in response to hypomorphic recessive alleles of ATR, the central mediator of the replication stress 
response, which is activated upon replication stress (49). 
 
      Several studies showed the involvement of Seckel syndrome-related genes in various 






NIN, CDK5RAP2, and PLK4), while some others (ATR, ATRIP, RBBP8, and DNA2) are important 
in maintaining genomic stability. 
 
      PLK4 is the master regulator of centrosome duplication and its deficiency has recently 
been associated with Seckel syndrome (53). However, the precise role of PLK4 in genomic 
stability and the DNA damage response is still unclear. According to Kalay et al. (32,112), mutated 
PLK4-Seckel fibroblasts obtained from patients revealed a G2/M delay, prolonged cell doubling 
time, impaired centriole biogenesis, and a disrupted mitotic morphology.  
 
      One plausible explanation of how different genetic deletions of centrosomal components 
in Seckel syndrome can lead to a similar outcome as the one caused by a mutation in ATR/ATRIP 
would be that centrosomes might contribute to ATR signaling. Moreover, CHK1, the downstream 
kinase of ATR, is associated with centrosomes, yet we could not detect the association of CHK1 
and centrosomes, and this could be due to numerous cross-reactions. Instead, our results 
strongly suggest that impaired centrosome composition triggers the translocation of MLK3, 
followed by activation of p38, MK2, and JUN. This signaling cascade induces replication stress, 
much like the deletion of ATR. These similar outcomes explain why the disruption of ATR signaling 
or centrosome integrity by genetic alterations can lead to very similar clinical conditions. It is 
conceivable to think that inhibiting or interfering with one or more partners of the activated stress 
pathway described in this thesis (MLK3-P38-MK2-JUN) might be beneficial for the treatment of 
patients with Seckel syndrome. For that purpose, we decided to evaluate the inhibition of MK2 in 
Seckel patient's cells. Although such patients are found rarely, this perspective remains to be 
assessed. As predicted, we managed to observe an improvement in DNA replication and cell 
proliferation in these cells after applying the MK2 inhibitor, and we also detected a lower level of 















7.8  Concluding remarks and future perspectives  
 
      In this thesis, we described strategies for targeting several centrosomal components using 
small-molecule inhibitors of PLK4, a centrosomal protein required for centrosome duplication, or 
using siRNAs targeting CEP152, SASS6, among others. We observed that PLK4 inhibition alone 
was sufficient to impair DNA replication and cause DNA damage independently of mitosis. We 
also reported that centrosomes, the microtubule organizing center of the eukaryotic cell, and the 
mitotic spindle support DNA replication by controlling the MLK3-p38-MK2 signaling cascade and 
suppress the formation of RNA:DNA hybrids (R-loops). This work establishes a mechanistic link 
between the duplications of two significant components that need to be replicated once every cell 
cycle, i. e. the cellular genome and the centrosomes.  
      To put this study in perspective, we also found that inhibiting the function of centrosomal 
proteins in several cell lines affected their ability to replicate their DNA faithfully. We also observed 
a significant decrease in cell proliferation upon centrosomal depletion in these cell lines.  
 
      In this work, we further increased our understanding of the role of centrosome duplication 
in cancer cells, and for the first time, we revealed a mutual regulation between two main processes 
happening in our cells - DNA replication and centrosome duplication. We showed that centrosome 
integrity during S phase is an essential factor for accurate DNA replication. Having a clear 
understanding of the pathways regulating centrosome integrity is of critical importance for 
therapeutic benefits.  
 
      For the past decades, there has been an increasing interest in understanding the 
mechanism that controls centriole duplication. The deeper understanding of the biology behind 
centrosome biogenesis will have significant ramifications to the development of therapeutic drugs. 
Developing drugs to target core components of the centrosome started with CFI-400945, which 
made it successfully to clinical trial phase II. CFI-400945 was firstly described as a potent PLK4 
inhibitor, yet later on, it was revealed that it could also target other centrosomal components, such 
as Aurora B (82). Following that, the discovery of Centrinone B took place. Centrinone B is 
considered to be a more specific PLK4 inhibitor, and even though this drug still has not made it 
to the clinical trials,  it managed to show promising results in in vitro studies (108). Despite that, 
Centrinone B only managed to reduce cell proliferation and in our case, induce replicative stress 
by generating R-loops without any signs of causing cell death, which could be used as a positive 






can be used to control cell proliferation, metastasis, and invasiveness through the regulation of 
actin cytoskeleton, as recently discussed by other researchers (152). More centrosomal 
components also need to be investigated as therapeutic targets to achieve centrosome depletion, 
such as CDK2, which is also implicated in DNA replication and centrosome duplication (10, 11, 
and 98) or PLK1 / Separase, which are required for licensing centriole duplication and controlling 
the number of newly generated centrioles (119,130).    
 
      Currently, we understand more about how these pathways are being activated upon 
centrosome impairment, but what needs to be further investigated is how these pathways function 
in vivo. We also lack animal models that mimick the phenotype caused by centrosome 
dysfunction, and it would be a critical achievement to generate such models. Having animal 
models mimicking centrosome dysfunctions would indeed increase our current understanding of 
human diseases. 
 
      An alternative approach to target centrosomes in cancer is by developing drugs that are 
able to suppress centrosome clustering. Cancer cells with centrosome amplification tend to 
cluster them to ensure bipolar spindle assembly, while healthy cells do not require this. Inhibiting 
centrosome clustering in cancer cells is expected to have a lethal outcome due to the multipolar 
division and therefore this could provide a promising treatment option for tumors with amplified 
centrosomes. CW069 (153) and CCB02 (154) are two compounds, which have attracted the 
attention of the scientific community recently. CW069 inhibits the microtubule motor protein 
HSET, which is crucial for centrosome clustering in cancer cells. Inhibition of HSET was reported 
to reduce centrosome clustering and cell growth in cancer cells, without affecting healthy cells. 
CCB02, a different compound, inhibits the interaction between centrosomal-P4.1-associated 
protein (CPAP) and tubulin, thereby enhancing microtubule nucleation and inhibiting the following 
centrosome clustering. 
 
      Lastly, instead of targeting centrosomal components directly, one could target proteins 
that control the response to abnormalities in centrosome duplication. Since we identified a new 
centrosomal component that plays a significant role in sensing centrosome abnormalities, 
MLK3/MK2, might be appropriate targets in cancer. In addition to that, USP28 (79), another 
protein that has been associated with the mitotic surveillance pathway, could also be targeted in 
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Supplementary Figure 1 
 
 


























Figure supplementary 1: MAP3K1 depleting prevents the activation of p38/MK2 in the H1299 cell 
line.  
 
(A)  MAP3K1 depletion rescues DNA replication when centrosomal components are removed by pool 
siRNA. Synchronized H1299 cells were reverse transfected with 10 nM siRNAs against the targets MAP3K1 








(B) MAP3K1 knockdown diminishes p38/MK2 activation upon centrosome depletion. Upon transfection as 
in (A), pathway activation was detected by phospho-specific antibodies.  
(C) protein-protein interaction using the STRING online tool. The STRING database contains information 
from numerous sources, including experimental data, computational prediction methods, and public text 
collections 
 
Supplementary Table 1: Phosphoproteomics reveals a significant phosphorylation level of 
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S 4.2971 0.24878 
285 MAP3K1 
(T285) 
T 4.2971 0.24878 
292 MAP3K1 
(S292) 
S 3.8358 0.24605 
507 MAP3K1 
(S507) 
S 2.6874 0.28236 
170 SQSTM1 
(S170) 
S 3.2842 0.32253 
307 
 
CHEK1 (S307) S 1.504 0.71324 
1068 
 
MDC1 (S1068) S 1.6194 0.47734 
1567 
 
MDC1 (T1567) T 1.9761 0.52428 
1664 
 









Phosphoproteomics reveals a significant phosphorylation level of MAP3K1, CHK1, after Centrinone 
B treatment in H1299.  
 
(A)  Table.1 shows the most unregulated proteins upon Centrinone B treatment. Labeled synchronized 
H1299 cells were treated with 500nM Centrinone B for 48hours then subjected to Masspec analysis.  
 
(B) Table 2 shows the log2 of the most unregulated proteins upon Centrinone B treatment as in (A).  
 
 (C) The bar plot shows selected proteins associated with a DNA stress response that is significantly 
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